

BioStem Technologies, Inc.
2836 Center Port Circle, Pompano Beach, FL 33064

(954)-380-8342
www.biostemtech.com
info@biostemtech.com

Quarterly Report

For the period ending September 30, 2025 (the "Reporting Period")

Outstanding Shares

The number of shares outstanding of our Common Stock was:

16,783,341 as of September 30, 2025 *(Current Reporting Period Date or More Recent Date)*

16,735,908 as of June 30, 2025 *(Current Reporting Period Date or More Recent Date)*

16,703,407 as of March 31, 2025 *(Current Reporting Period Date or More Recent Date)*

16,653,876 as of December 31, 2024 *(Most Recent Completed Fiscal Year End)*

Shell Status

Indicate by check mark whether the company is a shell company (as defined in Rule 405 of the Securities Act of 1933, Rule 12b-2 of the Exchange Act of 1934 and Rule 15c2-11 of the Exchange Act of 1934):

Yes: ☐ No: ☒

Indicate by check mark whether the company's shell status has changed since the previous reporting period:

Yes: ☐ No: ☒

Change in Control

Indicate by check mark whether a Change in Control⁵ of the company has occurred during this reporting period:

⁵ "Change in Control" shall mean any events resulting in:

- (i) Any "person" (as such term is used in Sections 13(d) and 14(d) of the Exchange Act) becoming the "beneficial owner" (as defined in Rule 13d-3 of the Exchange Act), directly or indirectly, of securities of the Company representing fifty percent (50%) or more of the total voting power represented by the Company's then outstanding voting securities;
- (ii) The consummation of the sale or disposition by the Company of all or substantially all of the Company's assets;

Yes: ☐

No: ☒

1) Name and address(es) of the issuer and its predecessors (if any)

In answering this item, provide the current name of the issuer and names used by predecessor entities, along with the dates of the name changes.

- a. BioStem Technologies, Inc. (Active)
- b. BioStem Technologies was formerly named Caribbean International Holdings, Inc., until August 28, 2014, when the issuer changed its name to BioStem Technologies, Inc.
- c. Caribbean International Holdings, Inc. was formerly named Caribbean Casino & Gaming Corporation, until November 29, 2012, when it changed its name to Caribbean International Holdings, Inc.
- d. Caribbean Casino & Gaming Corporation was formed on February 12, 2009.

Current State and Date of Incorporation or Registration: Florida, August 28, 2014

Standing in this jurisdiction: (e.g. active, default, inactive): Active

Prior Incorporation Information for the issuer and any predecessors during the past five years:
None

Describe any trading suspension or halt orders issued by the SEC or FINRA concerning the issuer or its predecessors since inception:

None

List any company name change, stock split, dividend, recapitalization, merger, acquisition, spin-off, or reorganization either currently anticipated or that occurred within the past 12 months:

None

Address of the issuer's principal executive office:

2836 Center Port Circle, Pompano Beach, FL 33064

Address of the issuer's principal place of business:

☒ *Check if principal executive office and principal place of business are the same address:*

Has the issuer or any of its predecessors been in bankruptcy, receivership, or any similar proceeding in the past five years?

No: ☒

Yes: ☐ If Yes, provide additional details below:

2) Security Information

(iii) A change in the composition of the Board occurring within a two (2)-year period, as a result of which fewer than a majority of the directors are directors immediately prior to such change; or

(iv) The consummation of a merger or consolidation of the Company with any other corporation, other than a merger or consolidation which would result in the voting securities of the Company outstanding immediately prior thereto continuing to represent (either by remaining outstanding or by being converted into voting securities of the surviving entity or its parent) at least fifty percent (50%) of the total voting power represented by the voting securities of the Company or such surviving entity or its parent outstanding immediately after such merger or consolidation.

Transfer Agent

Name: V Stock Transfer
Phone: 212-828-8436
Email: info@vstocktransfer.com
Address: 18 Lafayette Pl, Woodmere, NY 11598

Publicly Quoted or Traded Securities:

The goal of this section is to provide a clear understanding of the share information for its publicly quoted or traded equity securities. Use the fields below to provide the information, as applicable, for all outstanding classes of securities that are publicly traded/quoted.

Trading symbol:	<u>BSEM</u>	
Exact title and class of securities outstanding:	<u>COMMON</u>	
CUSIP:	<u>090684200</u>	
Par or stated value:	<u>\$0.001</u>	
Total shares authorized:	<u>975,000,000</u>	as of date: <u>September 30, 2025</u>
Total shares outstanding:	<u>16,783,341</u>	as of date: <u>September 30, 2025</u>
Total number of shareholders of record:	<u>293</u>	as of date: <u>September 30, 2025</u>

Please provide the above-referenced information for all other publicly quoted or traded securities of the issuer.

N/A

Other classes of authorized or outstanding equity securities that do not have a trading symbol:

The goal of this section is to provide a clear understanding of the share information for its other classes of authorized or outstanding equity securities (e.g., preferred shares that do not have a trading symbol). Use the fields below to provide the information, as applicable, for all other authorized or outstanding equity securities.

Exact title and class of the security:	<u>Series A-1 Preferred Stock</u>	
Par or stated value:	<u>\$0.001</u>	
Total shares authorized:	<u>300</u>	as of date: <u>September 30, 2025</u>
Total shares outstanding:	<u>300</u>	as of date: <u>September 30, 2025</u>
Total number of shareholders of record:	<u>3</u>	as of date: <u>September 30, 2025</u>

Please provide the above-referenced information for all other classes of authorized or outstanding equity securities.

Exact title and class of the security:	<u>Series B-1 Preferred Stock</u>	
CUSIP (if applicable):	<u>NA</u>	
Par or stated value:	<u>\$0.001</u>	
Total shares authorized:	<u>500,000</u>	as of date: <u>September 30, 2025</u>
Total shares outstanding (if applicable):	<u>5</u>	as of date: <u>September 30, 2025</u>
Total number of shareholders of record (if applicable):	<u>1</u>	as of date: <u>September 30, 2025</u>

Security Description:

The goal of this section is to provide a clear understanding of the material rights and privileges of the securities issued by the company. Please provide the below information for each class of the company's equity securities, as applicable:

1. For common equity, describe any dividend, voting and preemption rights.

Each holder is entitled to one vote for each share of Common Stock held on all matters submitted to a vote of stockholders of the Company. Holders of Common Stock are not entitled to any preemptive rights.

2. For preferred stock, describe the dividend, voting, conversion, and liquidation rights as well as redemption or sinking fund provisions.

Series A-1 Convertible Preferred Shares:

The Company has designated 300 shares of preferred stock as "Series A-1 Convertible Preferred Shares". The Series A-1 Convertible Preferred Shares entitled their holders to a number of votes equal to the number of shares issuable upon conversion times 2,000,000 granting the holders of Series A-1 Convertible Preferred Shares, as a group, effective control of the Company.

Series A-1 Convertible Preferred Shares are convertible, at the option of the holders, or automatically upon a Qualified Public Offering resulting in gross proceeds to the Company of not less than \$30 million, in whole but not in part, into 300 shares of common stock.

Holders of Series A-1 Convertible Preferred Shares are not entitled to receive dividends out of assets legally available thereof, prior and in preference to any declaration or payment of any dividend on the common stock or any other capital stock of the Corporation.

Series B-1 Convertible Preferred Shares:

The Company has designated 500,000 shares of preferred stock as "Series B-1 Convertible Preferred Shares".

The Series B-1 Convertible Preferred Shares entitle their holders to votes equal to the number of shares issuable upon conversion.

Each Series B-1 Convertible Preferred Share is convertible, at the option of the holders, or automatically upon a Qualified Public Offering resulting in gross proceeds to the Company of not less than \$30 million, in whole but not in part, into five (5) shares of common stock.

The Series B-1 Preferred Shares shall be entitled to receive an annual dividend, payable in newly issued common stock, in an amount equal to ten percent (10%) of the number of then existing Series B-1 Preferred Shares issued and outstanding prior and in preference to any declaration or payment of any dividend on the common stock or any other capital stock of the Corporation. This Dividend shall be cumulative.

3. Describe any other material rights of common or preferred stockholders.

None

4. Describe any material modifications to rights of holders of the company's securities that have occurred over the reporting period covered by this report.

None

3) Issuance History

The goal of this section is to provide disclosure with respect to each event that resulted in any changes to the total shares outstanding of any class of the issuer's securities **in the past two completed fiscal years and any subsequent interim period.**

Disclosure under this item shall include, in chronological order, all offerings and issuances of securities, including debt convertible into equity securities, whether private or public, and all shares, or any other securities or options to acquire such securities, issued for services. Using the tabular format below, please describe these events.

A. Changes to the Number of Outstanding Shares for the two most recently completed fiscal years and any subsequent period.

Indicate by check mark whether there were any changes to the number of outstanding shares within the past two completed fiscal years:

No: ☐ Yes: ☒ (If yes, you must complete the table below)

Shares Outstanding <u>Opening Balance</u> :			*Right-click the rows below and select "Insert" to add rows as needed.						
Date <u>12/31/2023</u> Common: <u>16,251,892</u> Preferred Series A-1: <u>300</u> Preferred Series B-1: <u>5</u>									
Date of Transaction	Transaction type (e.g., new issuance, cancellation, shares returned to treasury)	Number of Shares Issued (or cancelled)	Class of Securities	Value of shares issued (\$/per share) at Issuance	Were the shares issued at a discount to market price at the time of issuance? (Yes/No)	Individual/ Entity Shares were issued to. ***You must disclose the control person(s) for any entities listed.	Reason for share issuance (e.g. for cash or debt conversion) - OR- Nature of Services Provided	Restricted or Unrestricted as of this filing.	Exemption or Registration Type.
1/1/2024	New Issuance	194	Common	5.15	No	JEFFREY K HARRISON	COMPENSATION FOR SCIENTIFIC ADVISORY BOARD SERVICES	RESTRICTED	RULE 4(a)(2)
1/1/2024	New Issuance	194	Common	5.15	No	SHAUN OPIE	COMPENSATION FOR SCIENTIFIC ADVISORY BOARD SERVICES	RESTRICTED	RULE 4(a)(2)
1/1/2024	New Issuance	194	Common	5.15	No	PHYSIOMICS SYSTEMS, LLC / DAN SHELLY	COMPENSATION FOR SCIENTIFIC ADVISORY BOARD SERVICES	RESTRICTED	RULE 4(a)(2)
1/4/2024	New Issuance	2,942	Common	5.17	No	OLYMPUS 3 ACQUISITIONS, LLC / CHRIS LEONE	SECURITY CONVERSION	RESTRICTED	RULE 4(a)(2)
1/8/2024	New Issuance	12,500	Common	2.00	No	WES DE SOUZA	SECURITY CONVERSION	RESTRICTED	RULE 4(a)(2)
1/30/2024	New Issuance	50,000	Common	2.00	No	JOSEPH LOMBAS	SECURITY CONVERSION	RESTRICTED	RULE 4(a)(2)

2/1/2024	New Issuance	167	Common	6.00	No	JEFFREY K HARRISON	COMPENSATION FOR SCIENTIFIC ADVISORY BOARD SERVICES	RESTRICTED	RULE 4(a)(2)
2/1/2024	New Issuance	167	Common	6.00	No	SHAUN OPIE	COMPENSATION FOR SCIENTIFIC ADVISORY BOARD SERVICES	RESTRICTED	RULE 4(a)(2)
2/1/2024	New Issuance	167	Common	6.00	No	PHYSIOMICS SYSTEMS, LLC / DAN SHELLEY	COMPENSATION FOR SCIENTIFIC ADVISORY BOARD SERVICES	RESTRICTED	RULE 4(a)(2)
2/6/2024	New Issuance	25,000	Common	2.00	No	JOSHUA J. GOODEN	SECURITY CONVERSION	RESTRICTED	RULE 4(a)(2)
3/1/2024	New Issuance	115	Common	8.72	No	JEFFREY K HARRISON	COMPENSATION FOR SCIENTIFIC ADVISORY BOARD SERVICES	RESTRICTED	RULE 4(a)(2)
3/1/2024	New Issuance	115	Common	8.72	No	SHAUN OPIE	COMPENSATION FOR SCIENTIFIC ADVISORY BOARD SERVICES	RESTRICTED	RULE 4(a)(2)
3/1/2024	New Issuance	115	Common	8.72	No	PHYSIOMICS SYSTEMS, LLC / DAN SHELLEY	COMPENSATION FOR SCIENTIFIC ADVISORY BOARD SERVICES	RESTRICTED	RULE 4(a)(2)
4/1/2024	New Issuance	106	Common	9.39	No	JEFFREY K HARRISON	COMPENSATION FOR SCIENTIFIC ADVISORY BOARD SERVICES	RESTRICTED	RULE 4(a)(2)
4/1/2024	New Issuance	106	Common	9.39	No	SHAUN OPIE	COMPENSATION FOR SCIENTIFIC ADVISORY BOARD SERVICES	RESTRICTED	RULE 4(a)(2)
4/1/2024	New Issuance	106	Common	9.39	No	PHYSIOMICS SYSTEMS, LLC / DAN SHELLEY	COMPENSATION FOR SCIENTIFIC ADVISORY BOARD SERVICES	RESTRICTED	RULE 4(a)(2)
4/8/2024	New Issuance	60,000	Common	10.78	No	PCG ADVISORY, INC. / JEFF RAMSOM	SERVICES RENDERED	RESTRICTED	RULE 4(a)(2)
4/12/2024	Shares Returned to Treasury	(117,359)	Common	N/A	No	MAXIM PARTNERS LLC / CLIFFORD A. TELLER	SHARES RETURNED TO TREASURY	RESTRICTED	RULE 4(a)(2)
5/1/2024	New Issuance	88	Common	11.31	No	JEFFREY K HARRISON	COMPENSATION FOR SCIENTIFIC ADVISORY BOARD SERVICES	RESTRICTED	RULE 4(a)(2)
5/1/2024	New Issuance	88	Common	11.31	No	SHAUN OPIE	COMPENSATION FOR SCIENTIFIC ADVISORY BOARD SERVICES	RESTRICTED	RULE 4(a)(2)
5/1/2024	New Issuance	88	Common	11.31	No	PHYSIOMICS SYSTEMS, LLC / DAN SHELLEY	COMPENSATION FOR SCIENTIFIC ADVISORY BOARD SERVICES	RESTRICTED	RULE 4(a)(2)

6/1/2024	New Issuance	119	Common	8.40	No	JEFFREY K HARRISON	COMPENSATION FOR SCIENTIFIC ADVISORY BOARD SERVICES	RESTRICTED	RULE 4(a)(2)
6/1/2024	New Issuance	119	Common	8.40	No	SHAUN OPIE	COMPENSATION FOR SCIENTIFIC ADVISORY BOARD SERVICES	RESTRICTED	RULE 4(a)(2)
6/1/2024	New Issuance	119	Common	8.40	No	PHYSIOMICS SYSTEMS, LLC / DAN SHELLEY	COMPENSATION FOR SCIENTIFIC ADVISORY BOARD SERVICES	RESTRICTED	RULE 4(a)(2)
7/1/2024	New Issuance	127	Common	7.88	No	JEFFREY K HARRISON	COMPENSATION FOR SCIENTIFIC ADVISORY BOARD SERVICES	RESTRICTED	RULE 4(a)(2)
7/1/2024	New Issuance	127	Common	7.88	No	SHAUN OPIE	COMPENSATION FOR SCIENTIFIC ADVISORY BOARD SERVICES	RESTRICTED	RULE 4(a)(2)
7/1/2024	New Issuance	127	Common	7.88	No	PHYSIOMICS SYSTEMS, LLC / DAN SHELLEY	COMPENSATION FOR SCIENTIFIC ADVISORY BOARD SERVICES	RESTRICTED	RULE 4(a)(2)
7/1/2024	New Issuance	127	Common	7.88	No	OLYMPUS 3 ACQUISITIONS, LLC / CHRIS LEONE	STOCK ISSUED FOR CASH	RESTRICTED	RULE 4(a)(2)
7/1/2024	New Issuance	20,000	Common	2.00	No	EDWARD AND JULIE WALDRON JTWS / EDWARD AND JULIE WALDRON TRUSTEES	SECURITY CONVERSION / EXERCISE OF WARRANT	RESTRICTED	RULE 4(a)(2)
7/1/2024	New Issuance	13,334	Common	2.00	No	EMERY WALDRON	SECURITY CONVERSION / EXERCISE OF WARRANT	RESTRICTED	RULE 4(a)(2)
8/1/2024	New Issuance	16,667	Common	2.00	No	BEAR CREEK CAPITAL LLC / RAY OLIVER	SECURITY CONVERSION / EXERCISE OF WARRANT	RESTRICTED	RULE 4(a)(2)
8/1/2024	New Issuance	106	Common	9.43	No	JEFFREY K HARRISON	COMPENSATION FOR SCIENTIFIC ADVISORY BOARD SERVICES	RESTRICTED	RULE 4(a)(2)
8/1/2024	New Issuance	106	Common	9.43	No	SHAUN OPIE	COMPENSATION FOR SCIENTIFIC ADVISORY BOARD SERVICES	RESTRICTED	RULE 4(a)(2)
8/1/2024	New Issuance	106	Common	9.43	No	PHYSIOMICS SYSTEMS, LLC / DAN SHELLEY	COMPENSATION FOR SCIENTIFIC ADVISORY BOARD SERVICES	RESTRICTED	RULE 4(a)(2)
9/1/2024	New Issuance	89	Common	11.24	No	JEFFREY K HARRISON	COMPENSATION FOR SCIENTIFIC ADVISORY BOARD SERVICES	RESTRICTED	RULE 4(a)(2)
9/1/2024	New Issuance	89	Common	11.24	No	SHAUN OPIE	COMPENSATION FOR SCIENTIFIC ADVISORY BOARD SERVICES	RESTRICTED	RULE 4(a)(2)
9/1/2024	New Issuance	89	Common	11.24	No	PHYSIOMICS SYSTEMS, LLC / DAN SHELLEY	COMPENSATION FOR SCIENTIFIC ADVISORY	RESTRICTED	RULE 4(a)(2)

							BOARD SERVICES		
10/1/2024	New Issuance	100	Common	9.99	No	JEFFREY K HARRISON	COMPENSATION FOR SCIENTIFIC ADVISORY BOARD SERVICES	RESTRICTED	RULE 4(a)(2)
10/1/2024	New Issuance	100	Common	9.99	No	SHAUN OPIE	COMPENSATION FOR SCIENTIFIC ADVISORY BOARD SERVICES	RESTRICTED	RULE 4(a)(2)
10/1/2024	New Issuance	100	Common	9.99	No	PHYSIOMICS SYSTEMS, LLC / DAN SHELLY	COMPENSATION FOR SCIENTIFIC ADVISORY BOARD SERVICES	RESTRICTED	RULE 4(a)(2)
10/30/2024	New Issuance	280,000	Common	1.00	No	ZAHALSKY INVESTMENT HOLDINGS / MICHAEL ZAHALSKY	SECURITY CONVERSION / EXERCISE OF OPTION	RESTRICTED	RULE 4(a)(2)
11/1/2024	New Issuance	77	Common	13.04	No	JEFFREY K HARRISON	COMPENSATION FOR SCIENTIFIC ADVISORY BOARD SERVICES	RESTRICTED	RULE 4(a)(2)
11/1/2024	New Issuance	77	Common	13.04	No	SHAUN OPIE	COMPENSATION FOR SCIENTIFIC ADVISORY BOARD SERVICES	RESTRICTED	RULE 4(a)(2)
11/1/2024	New Issuance	77	Common	13.04	No	PHYSIOMICS SYSTEMS, LLC / DAN SHELLY	COMPENSATION FOR SCIENTIFIC ADVISORY BOARD SERVICES	RESTRICTED	RULE 4(a)(2)
11/27/2024	New Issuance	3,400	Common	3.38	No	INDRANEEL S. BHATTACHARYA	SECURITY CONVERSION / EXERCISE OF OPTION	RESTRICTED	RULE 4(a)(2)
12/1/2024	New Issuance	58	Common	17.35	No	JEFFREY K HARRISON	COMPENSATION FOR SCIENTIFIC ADVISORY BOARD SERVICES	RESTRICTED	RULE 4(a)(2)
12/1/2024	New Issuance	58	Common	17.35	No	SHAUN OPIE	COMPENSATION FOR SCIENTIFIC ADVISORY BOARD SERVICES	RESTRICTED	RULE 4(a)(2)
12/1/2024	New Issuance	58	Common	17.35	No	PHYSIOMICS SYSTEMS, LLC / DAN SHELLY	COMPENSATION FOR SCIENTIFIC ADVISORY BOARD SERVICES	RESTRICTED	RULE 4(a)(2)
12/15/2024	New Issuance	8,469	Common	9.84	No	JASON MATUSZEWSKI	SERVICES RENDERED	RESTRICTED	RULE 4(a)(2)
12/15/2024	New Issuance	1,694	Common	9.84	No	BRANDON POE	SERVICES RENDERED	RESTRICTED	RULE 4(a)(2)
12/15/2024	New Issuance	7,622	Common	9.84	No	ANDREW SMITH-VAN VURST	SERVICES RENDERED	RESTRICTED	RULE 4(a)(2)
12/15/2024	New Issuance	1,694	Common	9.84	No	THOMAS J. DUGAN	SERVICES RENDERED	RESTRICTED	RULE 4(a)(2)
12/15/2024	New Issuance	1,694	Common	9.84	No	PATRICK DALY	SERVICES RENDERED	RESTRICTED	RULE 4(a)(2)

12/15/2024	New Issuance	1,694	Common	9.84	No	KEN WARRINGTON	SERVICES RENDERED	RESTRICTED	RULE 4(a)(2)
12/15/2024	New Issuance	4,234	Common	9.84	No	SHAWN MCCARREY	SERVICES RENDERED	RESTRICTED	RULE 4(a)(2)
12/15/2024	New Issuance	4,234	Common	9.84	No	MICHAEL A FORTUNATO	SERVICES RENDERED	RESTRICTED	RULE 4(a)(2)
01/01/2025	New Issuance	67	Common	14.83	No	JEFFREY K HARRISON	COMPENSATION FOR SCIENTIFIC ADVISORY BOARD SERVICES	RESTRICTED	RULE 4(a)(2)
01/01/2025	New Issuance	67	Common	14.83	No	SHAUN OPIE	COMPENSATION FOR SCIENTIFIC ADVISORY BOARD SERVICES	RESTRICTED	RULE 4(a)(2)
01/01/2025	New Issuance	67	Common	14.83	No	PHYSIOMICS SYSTEMS, LLC / DAN SHELLY	COMPENSATION FOR SCIENTIFIC ADVISORY BOARD SERVICES	RESTRICTED	RULE 4(a)(2)
02/01/2025	New Issuance	68	Common	14.80	No	JEFFREY K HARRISON	COMPENSATION FOR SCIENTIFIC ADVISORY BOARD SERVICES	RESTRICTED	RULE 4(a)(2)
02/01/2025	New Issuance	68	Common	14.80	No	SHAUN OPIE	COMPENSATION FOR SCIENTIFIC ADVISORY BOARD SERVICES	RESTRICTED	RULE 4(a)(2)
02/01/2025	New Issuance	68	Common	14.80	No	PHYSIOMICS SYSTEMS, LLC / DAN SHELLY	COMPENSATION FOR SCIENTIFIC ADVISORY BOARD SERVICES	RESTRICTED	RULE 4(a)(2)
02/06/2025	New Issuance	16,667	Common	2.00	No	STEVE SIMON	SECURITY CONVERSION / EXERCISE OF WARRANT	RESTRICTED	RULE 4(a)(2)
02/21/2025	New Issuance	417	Common	15.37	No	DAVID GRODIN	SERVICES RENDERED	RESTRICTED	RULE 4(a)(2)
03/01/2025	New Issuance	69	Common	14.53	No	JEFFREY K HARRISON	COMPENSATION FOR SCIENTIFIC ADVISORY BOARD SERVICES	RESTRICTED	RULE 4(a)(2)
03/01/2025	New Issuance	69	Common	14.53	No	SHAUN OPIE	COMPENSATION FOR SCIENTIFIC ADVISORY BOARD SERVICES	RESTRICTED	RULE 4(a)(2)
03/01/2025	New Issuance	69	Common	14.53	No	PHYSIOMICS SYSTEMS, LLC / DAN SHELLY	COMPENSATION FOR SCIENTIFIC ADVISORY BOARD SERVICES	RESTRICTED	RULE 4(a)(2)
03/07/2025	New Issuance	500	Common	12.17	No	BARRY HASSETT	SERVICES RENDERED	RESTRICTED	RULE 4(a)(2)
03/17/2025	New Issuance	4,234	Common	10.75	No	MICHAEL A FORTUNATO	SERVICES RENDERED	RESTRICTED	RULE 4(a)(2)
03/17/2025	New Issuance	1,694	Common	10.75	No	BRANDON POE	SERVICES RENDERED	RESTRICTED	RULE 4(a)(2)

03/17/2025	New Issuance	8,469	Common	10.75	No	JASON MATUSZEWSKI	SERVICES RENDERED	RESTRICTED	RULE 4(a)(2)
03/17/2025	New Issuance	1,694	Common	10.75	No	KEN WARRINGTON	SERVICES RENDERED	RESTRICTED	RULE 4(a)(2)
03/17/2025	New Issuance	1,694	Common	10.75	No	PATRICK DALY	SERVICES RENDERED	RESTRICTED	RULE 4(a)(2)
03/17/2025	New Issuance	4,234	Common	10.75	No	SHAWN MCCARREY	SERVICES RENDERED	RESTRICTED	RULE 4(a)(2)
03/17/2025	New Issuance	1,694	Common	10.75	No	THOMAS J. DUGAN	SERVICES RENDERED	RESTRICTED	RULE 4(a)(2)
03/17/2025	New Issuance	7,622	Common	10.75	No	ANDREW SMITH-VAN VURST	SERVICES RENDERED	RESTRICTED	RULE 4(a)(2)
04/01/2025	New Issuance	89	Common	11.29	No	SHAUN OPIE	COMPENSATION FOR SCIENTIFIC ADVISORY BOARD SERVICES	RESTRICTED	RULE 4(a)(2)
05/01/2025	New Issuance	86	Common	11.65	No	SHAUN OPIE	COMPENSATION FOR SCIENTIFIC ADVISORY BOARD SERVICES	RESTRICTED	RULE 4(a)(2)
05/21/2025	New Issuance	417	Common	12.20	No	DAVID GRODIN	SERVICES RENDERED	RESTRICTED	RULE 4(a)(2)
06/01/2025	New Issuance	74	Common	13.46	No	SHAUN OPIE	COMPENSATION FOR SCIENTIFIC ADVISORY BOARD SERVICES	RESTRICTED	RULE 4(a)(2)
06/09/2025	New Issuance	500	Common	14.16	No	BARRY HASSETT	SERVICES RENDERED	RESTRICTED	RULE 4(a)(2)
06/16/2025	New Issuance	1,694	Common	13.65	No	BRANDON POE	SERVICES RENDERED	RESTRICTED	RULE 4(a)(2)
06/16/2025	New Issuance	8,469	Common	13.65	No	JASON MATUSZEWSKI	SERVICES RENDERED	RESTRICTED	RULE 4(a)(2)
06/16/2025	New Issuance	1,694	Common	13.65	No	KEN WARRINGTON	SERVICES RENDERED	RESTRICTED	RULE 4(a)(2)
06/16/2025	New Issuance	1,694	Common	13.65	No	PATRICK DALY	SERVICES RENDERED	RESTRICTED	RULE 4(a)(2)
06/16/2025	New Issuance	4,234	Common	13.65	No	SHAWN MCCARREY	SERVICES RENDERED	RESTRICTED	RULE 4(a)(2)
06/16/2025	New Issuance	1,694	Common	13.65	No	THOMAS DUGAN	SERVICES RENDERED	RESTRICTED	RULE 4(a)(2)
06/16/2025	New Issuance	7,622	Common	13.65	No	ANDREW SMITH-VAN VURST	SERVICES RENDERED	RESTRICTED	RULE 4(a)(2)
06/16/2025	New Issuance	4,234	Common	13.65	No	MICHAEL FORTUNATO	SERVICES RENDERED	RESTRICTED	RULE 4(a)(2)
7/01/2025	New Issuance	74	Common	13.45	No	SHAUN OPIE	COMPENSATION FOR SCIENTIFIC ADVISORY	RESTRICTED	RULE 4(a)(2)

							BOARD SERVICES		
7/11/2025	New Issuance	10,000	Common	1.50	No	JOHN S. RADTKE	SECURITY CONVERSION / EXERCISE OF WARRANT	RESTRICTED	RULE 4(a)(2)
8/01/2025	New Issuance	86	Common	11.58	No	SHAUN OPIE	COMPENSATION FOR SCIENTIFIC ADVISORY BOARD SERVICES	RESTRICTED	RULE 4(a)(2)
8/21/2025	New Issuance	417	Common	6.15	No	DAVID GRODIN	SERVICES RENDERED	RESTRICTED	RULE 4(a)(2)
9/1/2025	New Issuance	119	Common	8.42	No	SHAUN OPIE	COMPENSATION FOR SCIENTIFIC ADVISORY BOARD SERVICES	RESTRICTED	RULE 4(a)(2)
9/9/2025	New Issuance	500	Common	6.18	No	BARRY HASSETT	SERVICES RENDERED	RESTRICTED	RULE 4(a)(2)
9/15/2025	New Issuance	1,694	Common	4.98	No	THOMAS J. DUGAN	SERVICES RENDERED	RESTRICTED	RULE 4(a)(2)
9/15/2025	New Issuance	1,694	Common	4.98	No	PATRICK DALY	SERVICES RENDERED	RESTRICTED	RULE 4(a)(2)
9/15/2025	New Issuance	1,694	Common	4.98	No	KEN WARRINGTON	SERVICES RENDERED	RESTRICTED	RULE 4(a)(2)
9/15/2025	New Issuance	7,622	Common	4.98	No	ANDREW SMITH-VAN VURST	SERVICES RENDERED	RESTRICTED	RULE 4(a)(2)
9/15/2025	New Issuance	8,469	Common	4.98	No	JASON MATUSZEWSKI	SERVICES RENDERED	RESTRICTED	RULE 4(a)(2)
9/15/2025	New Issuance	4,234	Common	4.98	No	MICHAEL FORTUNATO	SERVICES RENDERED	RESTRICTED	RULE 4(a)(2)
9/15/2025	New issuance	1,694	Common	4.98	No	BRANDON POE	SERVICES RENDERED	RESTRICTED	RULE 4(a)(2)
Shares Outstanding on Date of This Report:									
Ending Balance:									
Date: 9/30/2025 Common: 16,783,341									
Preferred Series A-1: 300									
Preferred Series B-1: 5									

Example: A company with a fiscal year end of December 31st, 2024, in addressing this item for its Annual Report, would include any events that resulted in changes to any class of its outstanding shares from the period beginning on January 1, 2023 through December 31, 2024 pursuant to the tabular format above.

Any additional material details, including footnotes to the table are below:

N/A

B. Convertible Debt

The following is a complete list of the Company's Convertible Debt which includes all promissory notes, convertible notes, convertible debentures, or any other debt instruments convertible into a class of the issuer's equity securities. The table includes all issued or outstanding convertible debt at any time during the last complete fiscal year and any interim period between the last fiscal year end and the date of this Certification.

☒ Check this box to confirm the Company had no Convertible Debt issued or outstanding at any point during this period.

Date of Note Issuance	Principal Amount at Issuance (\$)	Outstanding Balance (\$) (include accrued interest)	Maturity Date	Conversion Terms (e.g., pricing mechanism for determining conversion of instrument to shares)	# Shares Converted to Date	# of Potential Shares to be Issued Upon Conversion ⁶	Name of Noteholder (entities must have individual with voting / investment control disclosed).	Reason for Issuance (e.g., Loan, Services, etc.)
N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Total Outstanding Balance: N/A

Total Shares: N/A

N/A

Any additional material details, including footnotes to the table are below:

N/A

4) Issuer's Business, Products and Services

The purpose of this section is to provide a clear description of the issuer's current operations. Ensure that these descriptions are updated on the Company's Profile on www.OTCMarkets.com.

- A. Summarize the issuer's business operations (If the issuer does not have current operations, state "no operations")

Organization and Description of the Business

BioStem Technologies, Inc. (hereinafter "the Company"), was incorporated as Aladdin & Company Trading in Utah on July 7, 2006. On March 2, 2009, Aladdin & Company Trading both changed its name to Caribbean Casino & Gaming Corporation and re-domiciled to Florida. Caribbean Casino & Gaming Corporation further changed its name to Caribbean International Holdings, Inc. on January 7, 2013. The Company then changed its name to BioStem Technologies, Inc. on August 28, 2014. The Company is active and currently in good standing with the State of Florida.

The Company's fiscal year end is December 31.

- B. List any subsidiaries, parent company, or affiliated companies.

On May 1, 2025 the Company filed Articles of Organization with the State of Florida and incorporated BioStem Properties, LLC, a new subsidiary 100% owned by BioStem Technologies, Inc.

In June 2024, the Company created Auxocell Operations Inc ("Auxocell"), a new subsidiary 100% owned by BioStem Technologies, Inc. Auxocell is domiciled in Nevada and holds all of the assets acquired in the Auxocell asset acquisition.

The Company also has a wholly-owned subsidiary, BioStem Life Sciences, Inc.

- C. Describe the issuers' principal products or services.

⁶ The total number of shares that can be issued upon full conversion of the Outstanding Balance. The number should not factor any "blockers" or limitations on the percentage of outstanding shares that can be owned by the Noteholder at a particular time. For purposes of this calculation, please use the current market pricing (e.g. most recent closing price, bid, etc.) of the security if conversion is based on a variable market rate.

BioStem Technologies is a leading innovator focused on harnessing the natural properties of perinatal tissue in the development, manufacture and commercialization of allografts and regenerative therapies. Leveraging our proprietary BioRetain® processing method, we manufacture perinatal tissue allografts at the highest levels of quality. BioRetain has been developed by applying the latest research in regenerative medicine, focused on maintaining natural growth factors and preserving tissue structure. Our allografts are trusted by top clinicians across a range of specialties.

5) Issuer's Facilities

The goal of this section is to provide investors with a clear understanding of all assets, properties or facilities owned, used or leased by the issuer and the extent in which the facilities are utilized.

In responding to this item, please clearly describe the assets, properties or facilities of the issuer. Describe the location of office space, data centers, principal plants, and other property of the issuer and describe the condition of the properties. Specify if the assets, properties, or facilities are owned or leased and the terms of their leases. If the issuer does not have complete ownership or control of the property, describe the limitations on the ownership.

The Company owns and operates a 6,100 sq. ft. manufacturing facility with multiple ISO 5 and ISO 7 suites designed for commercial production of human cells, tissues, and cellular based products ("HCT/PS"). The Company is currently in the process of expanding its manufacturing capacity by doubling its ISO clean room. The additional manufacturing capacity is expected to be operational by within the second half of 2024.

The Company also leases certain laboratory and office equipment accounted for as finance leases within the Company's financial statements.

On March 15, 2024, the Company entered into a thirty-eight month lease for office space commencing on April 1, 2024. The Company occupied its new expanded office space in Fort Lauderdale, Florida.

On April 14, 2025, the Company entered into a twenty-four month lease for office space commencing on May 15, 2025. The Company expanded its new office space in Fort Lauderdale, Florida.

6) All Officers, Directors, and 5% Beneficial Owners of the Company

Using the table below, please provide information, as of the period end date of this report, regarding all officers and directors of the company, or any person that performs a similar function, regardless of the number of shares they own.

In addition, list all individuals or entities controlling 5% or more of any class of the issuer's securities. If any insiders listed are corporate shareholders or entities, provide the name and address of the person(s) beneficially owning or controlling such corporate shareholders, or the name and contact information (City, State) of an individual representing the corporation or entity. Include Company Insiders who own any outstanding units or shares of any class of any equity security of the issuer.

The goal of this section is to provide investors with a clear understanding of the identity of all the persons or entities that are involved in managing, controlling or advising the operations, business development and disclosure of the issuer, as well as the identity of any significant or beneficial owners.

Individual Name (First, Last) or Entity Name (Include names of control person(s) if a corporate entity)	Position/Company Affiliation (ex: CEO, ≥ 5% beneficial owner)	City and State (Include Country if outside U.S.)	Number of Shares Owned (List common, preferred, warrants and options separately)	Class of Shares Owned	Percentage of Class of Shares Owned (undiluted)
Jason Matuszewski	<u>Officer, Director and Greater than 5% Stockholder</u>	Boca Raton, FL	<u>1,170,869</u> <u>100</u> <u>2,250,000</u>	Common Preferred A- 1 Fully Vested Common Stock Options	6.98% <u>33.33%</u>
Andrew Van Vurst	<u>Officer, Director and Greater than 5% Stockholder</u>	Lighthouse Point, FL	<u>1,452,449</u> <u>100</u> <u>2,250,000</u>	Common Preferred A- 1 Fully Vested Common Stock Options	8.65% <u>33.33%</u>
Henry Van Vurst	<u>Greater than 5% Stockholder</u>	Fort Lauderdale, FL	<u>1,093,579</u> <u>100</u>	Common Preferred A- 1	6.52% <u>33.33%</u>
Michael Fortunato	<u>Officer and Director</u>	Fort Lauderdale, FL	<u>46,936</u> <u>268,634</u>	Common Fully Vested Common Stock Options	<1%
Brandon Poe	<u>Director <5%</u>	San Diego, CA	<u>40,654</u>	Common	<1%
Kenneth Warrington	<u>Director <5%</u>	Gainesville, FL	<u>6,776</u> <u>7,462</u>	Common Fully Vested Common Stock Options	<1%
Patrick Daly	<u>Director <5%</u>	Raleigh, NC	<u>14,765</u>	Common	<1%
Thomas Dugan	<u>Director <5%</u>	Ponte Vedra Beach, FL	<u>19,168</u>	Common	<1%
Michael Dietzen	<u>Owner >5%</u>	Fort Lauderdale, FL	<u>1,000,000</u>	Common	5.96%

Confirm that the information in this table matches your public company profile on www.OTCMarkets.com. If any updates are needed to your public company profile, log in to www.OTCIQ.com to update your company profile.

7) Legal/Disciplinary History

A. Identify and provide a brief explanation as to whether any of the persons or entities listed above in Section 6 have, in the past 10 years:

1. Been the subject of an indictment or conviction in a criminal proceeding or plea agreement or named as a defendant in a pending criminal proceeding (excluding minor traffic violations);

None

2. Been the subject of the entry of an order, judgment, or decree, not subsequently reversed, suspended or vacated, by a court of competent jurisdiction that permanently or temporarily enjoined, barred, suspended or otherwise limited such person's involvement in any type of business, securities, commodities, financial- or investment-related, insurance or banking activities;

None

3. Been the subject of a finding, disciplinary order or judgment by a court of competent jurisdiction (in a civil action), the Securities and Exchange Commission, the Commodity Futures Trading Commission, a state securities regulator of a violation of federal or state securities or commodities law, or a foreign regulatory body or court, which finding or judgment has not been reversed, suspended, or vacated;

None

4. Named as a defendant or a respondent in a regulatory complaint or proceeding that could result in a "yes" answer to part 3 above; or

None

5. Been the subject of an order by a self-regulatory organization that permanently or temporarily barred, suspended, or otherwise limited such person's involvement in any type of business or securities activities.

None

6. Been the subject of a U.S Postal Service false representation order, or a temporary restraining order, or preliminary injunction with respect to conduct alleged to have violated the false representation statute that applies to U.S mail.

None

B. Describe briefly any material pending legal proceedings, other than ordinary routine litigation incidental to the business, to which the issuer or any of its subsidiaries is a party to or of which any of their property is the subject. Include the name of the court or agency in which the proceedings are pending, the date instituted, the principal parties thereto, a description of the factual basis alleged to underlie the proceeding and the relief sought. Include similar information as to any such proceedings known to be contemplated by governmental authorities.

None

8) Third Party Service Providers

Provide the name, address, telephone number and email address of each of the following outside providers. You may add additional space as needed.

Confirm that the information in this table matches your public company profile on www.OTCMarkets.com. If any updates are needed to your public company profile, update your company profile.

Securities Counsel

Name: Flora Perez, Esq
Address 1: 401 East Las Olas Blvd, Suite 2000
Address 2: Fort Lauderdale, Florida 33301
Phone: (954) 765-0500
Email: perezf@gtlaw.com

Accountant or Auditor

Name: Jonathon Ridgeway
Firm: KPMG, LLP
Address 1: 620 S. Tryon Avenue, Suite 1000
Address 2: Charlotte, North Carolina 28202
Phone: (704) 453-0679
Email: iridgeway@kpmg.com

Investor Relations

Name: Philip Taylor
Firm: Gilmartin Group
Address 1: 60 E Sir Francis Drake Blvd.
Address 2: Larkspur, CA 94939
Phone: (415) 937-5406
Email: philip@gilmartinir.com

All other means of Investor Communication:

X (Twitter): X BSEM Twitter (https://twitter.com/BSEM_Tech)
Discord: N/A
LinkedIn: [BSEM LinkedIn Page](#)
Facebook: N/A
[Other] [BSEM Instagram Link](#)

Other Service Providers

Provide the name of any other service provider(s) that **that assisted, advised, prepared, or provided information with respect to this disclosure statement**. This includes counsel, broker-dealer(s), advisor(s), consultant(s) or any entity/individual that provided assistance or services to the issuer during the reporting period.

Name: N/A
Firm: N/A
Nature of Services: N/A
Address 1: N/A

Address 2: N/A
Phone: N/A
Email: N/A

9) Disclosure & Financial Information

A. This Disclosure Statement was prepared by (name of individual):

Name: Michael Fortunato, CPA
Title: CAO
Relationship to Issuer: Officer

B. The following financial statements were prepared in accordance with:

- ☐ IFRS
☒ U.S. GAAP

C. The following financial statements were prepared by (name of individual):

Name: Michael Fortunato, CPA
Title: CAO
Relationship to Issuer: Officer

Describe the qualifications of the person or persons who prepared the financial statements:⁷ The CAO is a licensed CPA and has over 30 years of experience in accounting and financial reporting.

Provide the following qualifying financial statements:

- ☐ Audit letter, if audited;
- ☐ Balance Sheet;
- ☐ Statement of Income;
- ☐ Statement of Cash Flows;
- ☐ Statement of Retained Earnings (Statement of Changes in Stockholders' Equity);
- ☐ Financial Notes

Financial Statement Requirements:

- Financial statements must be published together with this disclosure statement as one document.
- Financial statements must be "machine readable." Do not publish images/scans of financial statements.
- Financial statements must be presented with comparative financials against the prior FYE or period, as applicable.
- Financial statements must be prepared in accordance with U.S. GAAP or International Financial Reporting Standards (IFRS) but are not required to be audited.

10) Issuer Certification

⁷ The financial statements requested pursuant to this item must be prepared in accordance with US GAAP or IFRS and by persons with sufficient financial skills.

Principal Executive Officer:

The issuer shall include certifications by the chief executive officer and chief financial officer of the issuer (or any other persons with different titles but having the same responsibilities) in each Quarterly Report or Annual Report.

The certifications shall follow the format below:

I, Jason V. Matuszewski certify that:

1. I have reviewed this Disclosure Statement for BioStem Technologies, Inc;
2. Based on my knowledge, this disclosure statement does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this disclosure statement; and
3. Based on my knowledge, the financial statements, and other financial information included or incorporated by reference in this disclosure statement, fairly present in all material respects the financial condition, results of operations and cash flows of the issuer as of, and for, the periods presented in this disclosure statement.

November 13, 2025

/s/ Jason Matuszewski

(Digital Signatures should appear as "/s/ [OFFICER NAME]")

Principal Financial Officer:

I, Michael A. Fortunato certify that:

1. I have reviewed this Disclosure Statement for BioStem Technologies, Inc;
2. Based on my knowledge, this disclosure statement does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this disclosure statement; and
3. Based on my knowledge, the financial statements, and other financial information included or incorporated by reference in this disclosure statement, fairly present in all material respects the financial condition, results of operations and cash flows of the issuer as of, and for, the periods presented in this disclosure statement.

November 13, 2025

/s/ Michael Fortunato

(Digital Signatures should appear as "/s/ [OFFICER NAME]")



BIOSTEM TECHNOLOGIES, INC. AND SUBSIDIARIES

CONSOLIDATED FINANCIAL STATEMENTS

**For the Three and Nine Months Ended September 30, 2025 and 2024
(Unaudited)**

Table of Contents

Unaudited Consolidated Balance Sheets as of September 30, 2025 and December 31, 2024	2
Unaudited Consolidated Statements of Operations for the Three and Nine Months Ended September 30, 2025 and 2024	3
Unaudited Consolidated Statements of Changes in Stockholders' Equity (Deficit) for the Three and Nine Months Ended September, 2025 and 2024	4
Unaudited Consolidated Statements of Cash Flows for the Nine Months Ended September 30, 2025 and 2024	6
Condensed Notes to the Unaudited Consolidated Financial Statements	7

BioStem Technologies, Inc. and Subsidiaries
Consolidated Balance Sheets
(Unaudited)

	As of September 30, 2025	As of December 31, 2024 (Restated)
Current Assets		
Cash and cash equivalents	\$ 27,158,117	\$ 22,832,706
Accounts receivable, net	20,104,929	23,107,027
Inventory	2,728,981	1,824,001
Short-term loan receivable	-	1,250,000
Prepaid expenses and other assets	2,699,667	2,874,317
Total current assets	52,691,694	51,888,051
Long-Term Assets		
Property and equipment, net	1,702,568	1,504,577
Construction-in-process	2,822,661	190,422
Right-of-use asset, net	374,790	271,214
Intangible assets, net	136,310	224,137
Goodwill	244,635	244,635
Deferred tax assets	4,420,185	4,179,632
Total assets	\$ 62,392,843	\$ 58,502,668
Current Liabilities		
Accounts payable and accrued expenses	\$ 4,586,098	\$ 5,289,786
License fees payable	907,839	2,359,575
Income tax payable	-	2,908,730
Accrued interest	2,160,000	1,962,983
Operating lease liabilities	228,759	106,723
Notes payable, net of discount	3,000,000	3,957,744
Other current liabilities	1,335,341	711,360
Total current liabilities	12,218,037	17,296,901
Long-Term Liabilities		
Operating lease liabilities, less current portion	158,397	180,235
Notes payable, less current portion	-	150,000
Total long-term liabilities	158,397	330,235
Total liabilities	12,376,434	17,627,136
Commitments and contingencies (Note 11)		
Stockholders' Equity		
Series A-1 convertible preferred stock, \$0.001 par value authorized, 300 shares; issued and outstanding, 300 shares as of September 30, 2025 and December 31, 2024	-	-
Series B-1 convertible preferred stock, \$0.001 par value authorized, 500,000 shares; issued and outstanding 5 shares as of September 30, 2025 and December 31, 2024.	-	-
Common stock, \$0.001 par value authorized, 975,000,000 shares issued and outstanding 16,783,341 and 16,661,482 shares as of September 30, 2025 and December 31, 2024, respectively.	16,784	16,662
Additional paid-in capital	59,102,980	54,642,012
Treasury stock, 18,000 shares at cost	(43,346)	(43,346)
Accumulated deficit	(9,060,009)	(13,739,796)
Total stockholders' equity	50,016,409	40,875,532
Total liabilities and stockholders' equity	\$ 62,392,843	\$ 58,502,668

See the Condensed Notes to the Unaudited Consolidated Financial Statements.

BioStem Technologies, Inc. and Subsidiaries
Consolidated Statements of Operations
(Unaudited)

	Three Months Ended September 30,		Nine Months Ended September 30,	
	2025	2024 (Restated)	2025	2024 (Restated)
Revenue, net	\$ 10,473,402	\$ 18,412,816	\$ 37,403,597	\$ 47,016,700
Cost of goods sold	1,204,794	4,238,658	2,743,409	10,211,258
Gross profit	9,268,608	14,174,158	34,660,188	36,805,442
Operating expenses:				
Sales and marketing expenses	1,305,957	1,027,764	3,704,484	2,784,872
General and administrative expenses	4,498,341	3,311,659	18,367,104	10,504,341
Research and development expenses	1,957,876	488,859	5,605,382	638,396
Depreciation and amortization expense	57,644	54,038	172,344	158,770
Total operating expenses	7,819,818	4,882,320	27,849,314	14,086,379
Income from operations	1,448,790	9,291,838	6,810,874	22,719,063
Other income (expense)				
Interest income (expense), net	143,284	(139,288)	239,686	(521,471)
Other expense	(123,345)	-	(123,345)	(2,497)
Other income (expense), net	19,939	(139,288)	116,341	(523,968)
Total income from operations before income taxes	1,468,729	9,152,550	6,927,215	22,195,095
Income tax expense	(707,677)	(2,332,648)	(2,247,428)	(5,831,273)
Net income	\$ 761,052	\$ 6,819,902	\$ 4,679,787	\$ 16,363,822
Basic net income per share attributable to common stockholders	\$ 0.05	\$ 0.42	\$ 0.28	\$ 1.00
Diluted net income per share attributable to common stockholders	\$ 0.03	\$ 0.32	\$ 0.20	\$ 0.79
Basic weighted average common shares outstanding	16,749,593	16,324,482	16,771,945	16,312,517
Diluted weighted average common shares outstanding	23,235,347	21,129,196	23,316,480	20,771,288

See the Condensed Notes to the Unaudited Consolidated Financial Statements.

BioStem Technologies, Inc. and Subsidiaries
Consolidated Statements of Changes in Stockholders' Equity
For the Three Months Ended September 30, 2025 and 2024
(Unaudited)

	Series A-1		Series B-1		Common Stock					Total Stockholders'
Three Months Ended September 30, 2025	Shares	Amount	Shares	Amount	Shares	Amount	Additional Paid-In Capital	Treasury Stock	Accumulated Deficit	Equity
Balance as of June 30, 2025	300	\$ -	5	\$ -	16,743,513	\$ 16,744	\$ 57,936,032	\$ (43,346)	\$ (9,821,061)	\$ 48,088,369
Stock based compensation - stock options	-	-	-	-	-	-	504,787	-	-	504,787
Issuance of common stock for services	-	-	-	-	279	-	3,000	-	-	3,000
Stock based compensation - restricted stock	-	-	-	-	29,549	30	644,171	-	-	644,201
Issuance of common stock for cash	-	-	-	-	10,000	10	14,990	-	-	15,000
Net income	-	-	-	-	-	-	-	-	761,052	761,052
Balance as of September 30, 2025	300	\$ -	5	\$ -	16,783,341	\$ 16,784	\$ 59,102,980	\$ (43,346)	\$ (9,060,009)	\$ 50,016,409

	Series A-1		Series B-1		Common Stock					Total Stockholders' Equity
	Shares	Amount	Shares	Amount	Shares	Amount	Additional Paid-In Capital	Treasury Stock	Accumulated Deficit	
<u>Three Months Ended September 30, 2024</u>										
Balance as of June 30, 2024	300	\$ -	5	\$ -	16,287,139	\$ 16,288	\$ 51,445,401	\$ (43,346)	\$ (36,080,697)	\$ 15,337,646
Stock based compensation-stock options	-	-	-	-	-	-	528,000	-	-	528,000
Issuance of common stock for services	-	-	-	-	1,296	1	45,159	-	-	45,160
Issuance of common stock for warrant exercises	-	-	-	-	50,001	50	99,952	-	-	100,002
Net income	-	-	-	-	-	-	-	-	6,820,403	6,820,403
Balance as of September 30, 2024	300	\$ -	5	\$ -	16,338,436	\$ 16,339	\$ 52,118,512	\$ (43,346)	\$ (29,260,294)	\$ 22,831,211

See the Condensed Notes to the Unaudited Consolidated Financial Statements.

BioStem Technologies, Inc. and Subsidiaries
Consolidated Statements of Changes in Stockholders' Equity
For the Nine Months Ended September 30, 2025 and 2024
(Unaudited)

	Series A-1		Series B-1		Common Stock					Total
Nine Months Ended September 30, 2025	Shares	Amount	Shares	Amount	Shares	Amount	Additional Paid-In Capital	Treasury Stock	Accumulated Deficit	Stockholders' Equity
Balance as of December 31, 2024	300	\$ -	5	\$ -	16,661,482	\$ 16,662	\$ 54,642,012	\$ (43,346)	\$ (13,739,796)	\$ 40,875,532
Stock based compensation - stock options	-	-	-	-	-	-	2,732,673	-	-	2,732,673
Stock based compensation - restricted stock	-	-	-	-	94,052	94	1,664,989	-	-	1,665,083
Issuance of common stock for services	-	-	-	-	1,140	1	14,999	-	-	15,000
Issuance of shares for warrant exercise	-	-	-	-	16,667	17	33,317	-	-	33,334
Issuance of common stock for cash	-	-	-	-	10,000	10	14,990	-	-	15,000
Net income	-	-	-	-	-	-	-	-	4,679,787	4,679,787
Balance as of September 30, 2025	300	\$ -	5	\$ -	16,783,341	\$ 16,784	\$ 59,102,980	\$ (43,346)	\$ (9,060,009)	\$ 50,016,409

	Series A-1		Series B-1		Common Stock					Total Stockholders' Equity
	Shares	Amount	Shares	Amount	Shares	Amount	Additional Paid-In Capital	Treasury Stock	Accumulated Deficit	
<u>Nine Months Ended September 30, 2024</u>										
Balance as of December 31, 2023	300	\$ -	5	\$ -	16,214,390	\$ 16,215	\$ 44,306,872	\$ (43,346)	\$ (45,624,117)	\$ (1,344,376)
Stock based compensation-stock options	-	-	-	-	-	-	4,458,557	-	-	4,458,557
Issuance of common stock for services	-	-	-	-	3,462	3	184,088	-	-	184,091
Conversion of debt and accrued interest to common stock	-	-	-	-	2,942	3	15,207	-	-	15,210
Issuance of common stock for cash received on warrant exercises	-	-	-	-	175,001	175	349,832	-	-	350,007
Issuance of common stock and warrants for prepaid services	-	-	-	-	60,000	60	2,803,840	-	-	2,803,900
Common stock repurchased and retired	-	-	-	-	(117,359)	(117)	116	-	-	(1)
Net income	-	-	-	-	-	-	-	-	16,363,823	16,363,823
Balance as of September 30, 2024	300	\$ -	5	\$ -	16,338,436	\$ 16,339	\$ 52,118,512	\$ (43,346)	\$ (29,260,294)	\$ 22,831,211

See the Condensed Notes to the Unaudited Consolidated Financial Statements.

BioStem Technologies, Inc. and Subsidiaries
Consolidated Statements of Cash Flows
For the Nine Months Ended September 30, 2025 and 2024
(Unaudited)

	Nine Months Ended September 30,	
	2025	2024
CASH FLOWS FROM OPERATING ACTIVITIES:		
Net income	\$ 4,679,787	\$ 16,363,823
Adjustments to reconcile net income to net cash provided by operating activities:		
Depreciation expense	84,518	66,031
Amortization expense	87,827	92,601
Amortization of debt discount	63,608	211,049
Amortization of right-of-use assets	110,644	45,300
Stock-based compensation expense - stock options and restricted stock	4,397,756	4,458,557
Issuance of common stock for services	15,000	184,091
Amortization of prepaid expenses paid with common stock and warrants	1,611,796	825,065
Deferred tax benefit	(240,553)	-
Provision for credit losses	-	175,000
Changes in operating assets and liabilities:		
Accounts receivable	3,002,098	(14,668,811)
Inventory	(904,980)	(1,414,570)
Prepaid expenses and other assets	(1,437,147)	(502,078)
Accounts payable and accrued expenses	(703,688)	1,203,893
License fees payable	(1,451,736)	2,687,850
Income tax payable	(2,908,730)	5,831,272
Accrued interest	197,017	198,471
Other current liabilities	623,981	577,179
Operating lease liabilities	(114,022)	(17,538)
Net cash provided by operating activities	7,113,176	16,317,185
CASH FLOWS FROM INVESTING ACTIVITIES:		
Short-term advance repaid (provided)	1,250,000	(1,250,000)
Purchases of property and equipment and construction-in-process	(2,914,747)	(295,238)
Net cash used in investing activities	(1,664,747)	(1,545,238)
CASH FLOWS FROM FINANCING ACTIVITIES:		
Repayments on notes payable	(1,171,352)	(738,883)
Repayments on finance leases	-	(8,988)
Issuance of stock for warrant exercises	33,334	350,007
Proceeds of sale of Common Stock	15,000	-
Common stock repurchased	-	(1)
Net cash used in financing activities	(1,123,018)	(397,865)
Cash and cash equivalents:		
Net change during the period	4,325,411	14,374,082
Balance, beginning of period	22,832,706	239,406
Balance, end of period	\$ 27,158,117	\$ 14,613,488
SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION:		
Cash paid for taxes	\$ 4,012,019	\$ -
Cash paid for interest	\$ 82,362	\$ 111,951
SCHEDULE OF NON-CASH INVESTING AND FINANCING ACTIVITIES:		
Conversion of debt and accrued interest to shares of common stock	\$ -	\$ 15,210
Construction-in-process transferred to property and equipment	\$ 32,849	\$ 202,700
Initial ROU asset and operating lease liability	\$ 214,220	\$ -
Issuance of common stock and warrants for prepaid services	\$ -	\$ 2,803,900
Right-of-use asset and liability	\$ -	\$ 340,401

See the Condensed Notes to the Unaudited Consolidated Financial Statements.

BioStem Technologies, Inc. and Subsidiaries
Condensed Notes to the Consolidated Financial Statements
For the Nine and Three Months Ended September 30, 2025 and 2024
(Unaudited)

Note 1 - Organization and Description of Business

BioStem Technologies, Inc. (hereinafter “the Company”), was incorporated as Aladdin & Company Trading in Utah on July 7, 2006. Aladdin & Company Trading later changed its name to Caribbean Casino & Gaming Corporation and re-domiciled in Florida on March 2, 2009. On January 7, 2013, Caribbean Casino & Gaming Corporation changed its name to Caribbean International Holdings, Inc. on January 7, 2013. On August 28, 2014, the Company changed its name to BioStem Technologies, Inc.

Since 2018, the Company’s primary business is the development, manufacture, and sale of tissue allografts for the advanced wound care market with a focus on the treatment of diabetic, pressure and venous ulcers. The Company markets and distributes products directly to medical professionals, such as podiatrists and plastic surgeons, through direct and indirect salesforces and indirectly through distributors.

The Company’s fiscal year ends December 31.

Note 2 - Summary of Significant Accounting Policies

Basis of Presentation and Consolidation

The consolidated financial statements of the Company are presented in United States dollars and have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”). In the opinion of management, the Company has made all necessary adjustments, which include normal recurring adjustments, for a fair statement of the Company’s consolidated financial position and results of operations for the periods presented. Certain information and disclosures included in these interim consolidated financial statements have been condensed or omitted pursuant to the U.S. Securities and Exchange Commission (“SEC”) rules. These condensed consolidated financial statements should be read in conjunction with our audited consolidated financial statements and accompanying notes for the year ended December 31, 2024, as filed with the Over-the-Counter (“OTC”) Market on April 15, 2025. The results for the three and nine months ended September 30, 2025 and 2024, are not necessarily indicative of the results to be expected for a full year, any other interim periods or any future year or periods.

The accompanying condensed unaudited consolidated financial statements include the accounts of BioStem Technologies, Inc. and all its wholly owned subsidiaries BioStem Life Sciences, Inc., Auxocell Operations Inc., and BioStem Properties, LLC. All intercompany transactions have been eliminated in consolidation.

Use of Estimates

The preparation of these interim unaudited consolidated financial statements in conformity with US GAAP requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes.

Such estimates and assumptions impact both assets and liabilities, including but not limited to net realizable value of accounts receivable and inventory, estimated useful lives and impairment of long-lived assets, the valuation of intangible assets, estimated fair value of stock-based payments, and the valuation of deferred tax assets.

Making estimates requires management to exercise significant judgment. It is at least reasonably possible that the estimate of the effect of a condition, situation or set of circumstances that existed at the date of the consolidated financial statements, which management considered in formulating its estimates could change in the near term due to one or more future non-conforming events. Accordingly, actual results could differ significantly from estimates.

BioStem Technologies, Inc. and Subsidiaries
Condensed Notes to the Consolidated Financial Statements
For the Three and Nine Months Ended September 30, 2025 and 2024
(Unaudited)

Risks and Uncertainties

The Company's operations are subject to risk and uncertainties including financial, operational, regulatory, and other risks including the potential risk of business failure.

The Company has experienced, and in the future expects to continue to experience, variability in its sales and earnings. The factors expected to contribute to this variability include, among others: (i) the uncertainty associated with the commercialization and ultimate success of the Company's products; (ii) competition inherent in the markets where products are expected to be sold; (iii) general economic conditions; and (iv) the related volatility of prices pertaining to the cost of sales.

Cash and Cash Equivalents

The Company considers cash and cash equivalents to include all stable, highly liquid investments with maturities, when acquired, of three months or less.

Concentrations of Risks

Financial instruments that subject the Company to concentration of risk consist primarily of cash and cash equivalents. The Company maintains its cash with large, high-credit quality financial institutions and, at times, such deposits may be more than federally insured limits. The Company's cash and cash equivalents consist of highly liquid investment accounts invested in U.S. Government backed securities. The Company has not experienced any losses on its deposits.

See Note 4 for customer concentration risks.

Summary of Significant Accounting Policies

The significant accounting policies applied in the Company's audited financial statements, as disclosed in its annual financial report filed with the OTC on April 15, 2025, are applied consistently in these interim unaudited consolidated financial statements.

Recently Issued Accounting Pronouncements Not Yet Adopted

In December 2023, Financial Accounting Standards Board ("FASB") issued Accounting Standard Update ("ASU"), *Income Taxes (Topic 740): Improvements to Income Tax Disclosures* ("ASU 2023-09"). The ASU focuses on income tax disclosures around effective tax rates and cash income taxes paid. ASU 2023-09 requires public business entities to disclose, on an annual basis, a rate reconciliation presented in both dollars and percentages. The guidance requires the rate reconciliation to include specific categories and provides further guidance on disaggregation of those categories based on a quantitative threshold equal to 5% or more of the amount determined by multiplying pretax income (loss) from continuing operations by the applicable statutory rate. For entities reconciling to the US statutory rate of 21%, this would generally require disclosing any reconciling items that impact the rate by 1.05% or more. ASU 2023-09 is effective for public business entities for annual periods beginning after Dec. 15, 2024 (generally, calendar year 2025) and effective for all other business entities one year later. Entities should adopt this guidance on a prospective basis, though retrospective application is permitted. The adoption of ASU 2023-09 is expected to have a financial statement disclosure impact only and is not expected to have a material impact on the Company's consolidated financial statements.

In November 2024, the FASB issued ASU2024-03, *Disaggregation of Income Statement Expenses (Subtopic 220-40)* (ASU 2024-03). ASU 2024-03 requires public entities to disaggregate, in a tabular presentation, certain income statement expenses into different categories, such as purchases of inventory, employee compensation, depreciation, and intangible asset amortization. The guidance is effective for fiscal years beginning after December 15, 2026, with

BioStem Technologies, Inc. and Subsidiaries
Condensed Notes to the Consolidated Financial Statements
For the Three and Nine Months Ended September 30, 2025 and 2024
(Unaudited)

early adoption permitted, and may be applied retrospectively. We are currently evaluating the impact of adopting ASU 2024-03 on our consolidated financial statements and related disclosures.

We reviewed all other recently issued accounting pronouncements and concluded that they were either not applicable or not expected to have a significant impact to the consolidated financial statements.

Other pronouncements issued by the FASB or other authoritative accounting standards groups with future effective dates are either not applicable or are not expected to be significant to the Company's financial position, results of operations or cash flows.

Note 3 - Inventory

Inventory is stated at the lower of cost or estimated net realizable value. Inventory cost is determined by the first-in, first-out ("FIFO") basis. Inventory costs include raw materials, labor and operating overhead which includes supplies, depreciation and amortization of leased lab equipment and other related costs.

The Company performs an assessment of the recoverability of inventory costs during each reporting period, and it provides an allowance for slow-moving, excess, and obsolete inventories to their estimated net realizable value in the period in which the need for an allowance is first identified. Such impairment charges are recorded within cost of goods sold. As of September 30, 2025 and December 31, 2024, the Company did not record any such impairments.

The table below presents the Company's inventory values, by category, as of September 30, 2025 and December 31, 2024, respectively:

	September 30, 2025	December 31, 2024
Raw Materials	\$ 308,370	\$ 176,218
Finished Goods	2,420,611	1,647,783
Total-gross value	2,728,981	1,824,001
Less: valuation allowance	-	-
Total net realizable value	\$ 2,728,981	\$ 1,824,001

Note 4 - Revenue Recognition and Contract Balances (Restated)

Revenue Recognition Policy

The Company records revenue from product sales in accordance with ASC 606, *Revenue from Contracts with Customers* ("ASC 606"). The core principle of ASC 606 is that an entity recognizes revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. Based on prior experience, and the nature of the product, variable consideration resulting from product discounts is not material.

Revenue is recognized in accordance with the core principle by applying the following five steps: 1) identifying contracts with a customer; 2) identifying the performance obligations in the contract; 3) determining the transaction price; 4) allocating the transaction price to the performance obligations; and 5) recognizing revenue upon the satisfaction a performance obligation.

The Company recognizes revenue from product sales at a point in time when control of the Company's product has transferred to the customer, which generally occurs upon shipment. Shipping and handling costs are included as a

BioStem Technologies, Inc. and Subsidiaries
Condensed Notes to the Consolidated Financial Statements
For the Three and Nine Months Ended September 30, 2025 and 2024
(Unaudited)

component of revenue and are passed through to customers with an equal offsetting amount included in cost of goods sold.

Revenue is recognized in an amount that reflects the consideration that the Company expects to receive in exchange for the product. The transaction price is adjusted for variable consideration, which may include rebates, incentives, or other forms of consideration payable to customers.

Returns from customers are not accepted. Accordingly, there is no provision for sales returns recorded for any period presented.

Distribution and Services Agreement

In September 2023, the Company executed a distribution and services agreement (“D&S Agreement”) with a large medical distributor located in the United States (the “Distributor”) for the distribution of the Company’s Amnio Wrap 2 (“AW2”) product. The Company licenses the rights to manufacture and commercialize AW2 from an unrelated party and in conjunction with the licensing arrangement, pays a per square centimeter license fee for all AW2 products sold by the Distributor. In October 2024, the Company executed an amendment to the D&S Agreement to expand the product lines that the Distributor will distribute on behalf of the Company and beginning in the fourth quarter of 2024, includes Vendaje AC (“VAC”). No licensing fees are due on VAC as the Company owns the right to manufacture and commercialize VAC.

The Distributor purchases AW2 and VAC from the Company at a fixed fee per square centimeter (“Sales Price”) with no right of return. Separately, the Distributor invoices the Company monthly for sales, marketing and distribution services it provides on behalf of the Company (“Bona Fide Services Fee or BFSF”).

Consideration Payable to Customers

At inception of the D&S Agreement, the Company assessed the consideration payable to the customer to determine if the payments were made in exchange for distinct goods or services received from the customer. The Company has concluded that the BFSF is not a distinct service provided by our distributor customer as these services cannot be separated from the sale of our goods to the customer.

Therefore, in accordance with ASC 606-10-32-25-27, we reflect the BFSF as a reduction of revenue when the related sale occurs which is when the payable is incurred. Accounts payable associated with the BFSF are included within accounts receivable due from the Distributor customer as a contra asset.

Revenue Details

A summary of net revenues earned from the sale of AW2 and VAC and the Bona Fide Services Fees incurred under the D&S agreement for the three and nine months ended is as follows:

	Three Months Ended September 30,		Nine Months Ended September 30,	
	2025	2024	2025	2024
D&S revenue, gross	\$ 46,886,672	\$ 82,253,800	\$ 168,546,175	\$ 197,812,300
Less: Bona fide service fees	(36,551,149)	(64,143,924)	(131,445,561)	(151,936,249)
D&S revenue, net	10,335,523	18,109,876	37,100,614	45,876,051
Other revenue	137,879	302,940	302,983	1,140,649
Total revenue, net	\$ 10,473,402	\$ 18,412,816	\$ 37,403,597	\$ 47,016,700

The BFSF is reflected as a reduction of revenue related to consideration payable to our customer for services which we have determined do not represent distinct services. During the three months ended September 30, 2025 and 2024, revenues generated under the D&S Agreement were approximately 100% of total revenues. During the nine months ended September 30, 2025 and 2024, revenues generated under the D&S Agreement were approximately 100% and 99% of total revenues, respectively

BioStem Technologies, Inc. and Subsidiaries
Condensed Notes to the Consolidated Financial Statements
For the Three and Nine Months Ended September 30, 2025 and 2024
(Unaudited)

As of September 30, 2025 and December 31, 2024, accounts receivable from the Distributor, net of BFSF payable were \$20,103,886 and \$23,099,404, respectively.

Accounts receivable represent the Company's unconditional rights to consideration under the contractual terms of the D&S Agreement. Accounts receivable are carried at the original invoice amount less an allowance for credit losses which is based upon historical loss patterns, the number of days that billings are past due, an evaluation of the potential risk of loss associated with delinquent accounts and current market conditions and reasonable and supportable forecasts of future economic conditions to form adjustments to historical loss patterns. The Company expects to collect the outstanding balance of current accounts receivable within the next twelve months. Therefore, estimates for credit losses were not significant as of September 30, 2025 and December 31, 2024.

The BFSF payable is paid upon receipt of cash to settle the outstanding accounts receivable.

Customer Credit Concentration

As disclosed above, the majority of our consolidated revenues are generated from the D&S Agreement we have with one distributor customer.

As of September 30, 2025 and December 31, 2024, approximately 100% of the outstanding accounts receivable were from invoices outstanding under the D&S Agreement.

The termination of the D&S Agreement could have an adverse impact on our financial position and results of operations.

Contract Costs

The Company incurs incremental costs to obtain contracts with its customers. These costs consist primarily of sales commissions paid to our sales force. As the expected period of amortization is not expected to exceed one year, the Company has elected to expense such costs as incurred.

Cost of Goods Sold

Cost of goods sold represents costs directly related to the production of the Company's products. Products sold are typically shipped directly to the customer with costs associated with shipping and handling included as a component of the cost of goods sold. Costs associated with any inventory write-downs resulting from quarterly physical inventory counts are also included in the cost of goods sold.

Note 5 - Net Income Per Share

Basic net income per share is computed by dividing the net income by the weighted-average number of common shares outstanding for the period. Diluted earnings per share is computed by adjusting the weighted-average number of common shares outstanding to include outstanding common stock options, restricted stock awards, warrants to purchase common stock, and convertible preferred stock. For periods in which the Company has reported net losses, diluted net loss per share is the same as basic net loss per share because dilutive common shares are not assumed to have been issued if their effect is anti-dilutive.

Basic and dilutive earnings per share is as follows for the three and nine months ended September 30, 2025 and 2024:

BioStem Technologies, Inc. and Subsidiaries
Condensed Notes to the Consolidated Financial Statements
For the Three and Nine Months Ended September 30, 2025 and 2024
(Unaudited)

	Three Months Ended September 30,		Nine Months Ended September 30,	
	2025	2024	2025	2024
Net income available to common shareholders (numerator)	\$ 761,052	\$ 6,819,902	\$ 4,679,787	\$ 16,363,822
Weighted-average number of common shares (denominator) - basic	16,749,593	16,324,482	16,771,945	16,312,517
Basic earnings per common share	\$ 0.05	\$ 0.42	\$ 0.28	\$ 1.00
Weighted-average number of common shares - basic	16,749,593	16,324,482	16,771,945	16,312,517
Potential shares of common stock arising from stock options, warrants, and unvested RSU's	6,485,754	4,804,714	6,544,535	4,458,772
Total shares-diluted (denominator)	23,235,347	21,129,196	23,316,480	20,771,289
Diluted earnings per common share	\$ 0.03	\$ 0.32	\$ 0.20	\$ 0.79

Note 6 - Property and Equipment and Construction-in-Process

The following table presents property and equipment as of September 30, 2025 and December 31, 2024:

	September 30, 2025	December 31, 2024
Building	\$ 433,448	\$ 433,448
Building Improvements	821,813	800,630
Land	75,000	75,000
Machinery and Equipment	1,361,960	1,259,372
Computer and Office Equipment	64,702	64,702
Furniture and Fixtures	226,802	68,066
Total property and equipment	2,983,725	2,701,218
Less: Accumulated depreciation	(1,281,157)	(1,196,640)
Total property and equipment, net	\$ 1,702,568	\$ 1,504,578
Construction-in-process	\$ 2,822,661	\$ 190,422

The construction-in-process consists of land and other costs incurred related to the construction of a manufacturing facility in Boca Raton, FL, which is in the process of being built.

Depreciation expense was \$31,551 and \$23,171 for the three months ended September 30, 2025 and 2024, respectively. Depreciation expense was \$84,518 and \$66,031 for the nine months ended September 30, 2025 and 2024, respectively.

Note 7 – Intangible Assets Other Than Goodwill

The Company's intangible assets were acquired in business combinations or asset acquisitions and are recognized at fair value using generally accepted valuation methods deemed appropriate for the type of intangible asset acquired and reported net of accumulated amortization, separately from goodwill.

Intangible assets with finite lives are amortized over their estimated useful lives. Intangible assets include developed technology, intellectual property, and customer relationships.

Amortization of intangible assets with finite lives is calculated on the straight-line method based on the following estimated useful lives:

BioStem Technologies, Inc. and Subsidiaries
Condensed Notes to the Consolidated Financial Statements
For the Three and Nine Months Ended September 30, 2025 and 2024
(Unaudited)

Website and software development costs	5 years
Intellectual property	5 years
Customer relationships	7 years

The following table presents intangible assets other than goodwill as of September, 2025 and December 31, 2024:

	As of September 30, 2025		
	Gross Carrying Amount	Accumulated Amortization	Net Carrying Amount
Intellectual property	\$ 152,000	\$ 101,250	\$ 50,750
Website and software development costs	225,907	140,347	85,560
Customer relationships	354,000	354,000	-
Total	<u>\$ 731,907</u>	<u>\$ 595,597</u>	<u>\$ 136,310</u>

	As of December 31, 2024		
	Gross Carrying Amount	Accumulated Amortization	Net Carrying Amount
Intellectual property	\$ 152,000	\$ 81,024	\$ 70,976
Website and software development costs	225,907	106,461	119,446
Customer relationships	354,000	320,285	33,715
Total	<u>\$ 731,907</u>	<u>\$ 507,770</u>	<u>\$ 224,137</u>

During the three months ended September 30, 2025 and 2024, amortization expense was \$26,093 and \$30,867 respectively. During the nine months ended September 30, 2025 and 2024, amortization expense was \$87,827 and \$92,740, respectively.

Future expected amortization expense of intangible assets is as follows:

Year Ending December 31,	Amount
2025 (remaining)	\$ 16,545
2026	66,181
2027	50,084
2028	3,500
Total	<u>\$ 136,310</u>

BioStem Technologies, Inc. and Subsidiaries
Condensed Notes to the Consolidated Financial Statements
For the Three and Nine Months Ended September 30, 2025 and 2024
(Unaudited)

Note 8 – Notes Payable

The following table presents the carrying value of the Company's notes payable as of September 30, 2025 and December 31, 2024:

	September 30, 2025	December 31, 2024
On July 27, 2018, the Company entered into a Bridge Loan Agreement and Promissory Note, with an interest rate of 0.50% per month for the first six months and 0.75% per month through the maturity date of July 27, 2019. This agreement has not been repaid on the maturity date and is currently in default (1).	\$ 1,000,000	\$ 1,000,000
On October 5, 2018, the Company entered into a Bridge Loan Agreement and Promissory Note, with an interest rate of 0.50%, per month for the first six months and 0.75% per month through the maturity date of October 5, 2019. This agreement has not been repaid on the maturity date and is currently in default (1).	2,000,000	2,000,000
On April 29, 2022, the Company entered an \$850,000 mortgage note at 8.25 percent per annum with a maturity date of May 1, 2024. Between June 1, 2022, and the maturity date, the Company was required to make monthly interest only payments of \$6,021 with a balloon payment of \$850,000 due May 1, 2025. The loan was secured by the corporate headquarters building. This loan was paid in full by the maturity date.	-	850,000
On May 18, 2020, the Company obtained a \$150,000 Economic Injury Disaster Loan. Installment payments, including principal and interest, of \$731 monthly, began 30 months from the promissory note or November 18, 2022. Interest will accrue at an annual rate of 3.75%. This loan has been repaid in full.	-	150,000
On June 1, 2023, the Company issued a promissory note in the amount of \$750,000 with an interest rate of 12.0% per annum. Between July 1, 2023 and the maturity date of May 25, 2025, the Company was required to make minimum monthly payments of principal and interest of \$35,305 monthly. The Note was an unsecured obligation (2). This note was paid in full by its maturity date.	-	171,352
Total notes payable	3,000,000	4,171,352
Less: unamortized discounts	-	(63,608)
Total notes payable	3,000,000	4,107,744
Less : current portion of notes payable, net of discount	(3,000,000)	(3,957,744)
Notes payable-long-term	\$ -	\$ 150,000

(1) In August 2019, the Company received notice from GMA Bridge Fund, LLC that the Company is in default for the loan that matured on July 27, 2019, for non-payment and gave the Company notice that the note which matured on October 5, 2019, was also in default. The Company continues to accrue interest on these loans and is in discussion with the lender to renegotiate the terms of these notes.

(2) In connection with the issuance of the \$750,000 promissory note, the lender received 373,134 common stock warrants with an exercise price of \$2.00 and exercise period of five years. The Company recorded a debt discount of \$305,310 based on the relative fair value of the warrants. The fair value of the warrants was determined using a Black-Scholes pricing model and the following assumptions: expected term 3 years, risk free interest rate of 3.98%, and volatility of 107.74%. For the nine months ended September 30, 2025 and 2024, the Company recognized amortization expense for this debt discount of \$63,608 and \$114,493, respectively, which is reflected in interest expense on the unaudited consolidated statements of operations. As of September 30, 2025 and December 31, 2024, the unamortized debt discount balance remaining was \$0 and \$63,607, respectively.

(3) During the year ended December 31, 2024, the Company repaid in full financing arrangements that included an aggregate of \$173,800 of original issue discount which was reflected as a debt discount and netted with the applicable note payable balance at issuance. The debt discount was amortized into interest expense over the term of the financing arrangements. During the nine months ended September 30, 2025 and 2024, the Company recognized amortization expense of \$0 and \$96,556, respectively, which is reflected in interest expense on the unaudited consolidated statements of operations.

Note 9 – Stockholders' Equity (Deficit)

BioStem Technologies, Inc. and Subsidiaries
Condensed Notes to the Consolidated Financial Statements
For the Three and Nine Months Ended September 30, 2025 and 2024
(Unaudited)

Series A-1 Convertible Preferred Shares

The Company has designated 300 shares of preferred stock with a par value of \$0.001 as “Series A-1 Convertible Preferred Shares”.

The Series A-1 Convertible Preferred Shares entitle their holders to a number of votes equal to the number of shares issuable upon conversion times 2,000,000 granting the holders of Series A-1 Convertible Preferred Shares, as a group, effective control of the Company.

Each Series A-1 Convertible Preferred Shares are convertible, at the option of the holders, or automatically upon a Qualified Public Offering resulting in gross proceeds to the Company of not less than \$30 million, in whole but not in part, into 300 shares of common stock.

Holders of Series A-1 Convertible Preferred Shares are not entitled to receive dividends, out of assets legally available thereof, prior and in preference to any declaration or payment of any dividend on the common stock or any other capital stock of the Corporation.

As of September 30, 2025 and December 31, 2024, there are 300 shares of Series A-1 Convertible Preferred Shares outstanding.

Series B-1 Convertible Preferred Shares

The Company has designated 500,000 shares of preferred stock with a par value of \$0.001 as “Series B-1 Convertible Preferred Shares”.

The Series B-1 Convertible Preferred Shares entitle their holders to votes equal to the number of shares issuable upon conversion.

Each Series B-1 Convertible Preferred Share is convertible, at the option of the holders, or automatically upon a Qualified Public Offering resulting in gross proceeds to the Company of not less than \$30 million, in whole but not in part, into 5 shares of common stock.

The Series B-1 Preferred Shares shall be entitled to receive an annual dividend, payable in newly issued common stock, in an amount equal to ten percent of the number of then existing Series B-1 Preferred Shares issued and outstanding prior and in preference to any declaration or payment of any dividend on the common stock or any other capital stock of the Corporation. This Dividend shall be cumulative.

As of September 30, 2025 and December 31, 2024, there are 5 shares of Series B-1 Convertible Preferred Shares outstanding.

Common Stock

The Company is authorized to issue 975,000,000 shares of common stock with a par value of \$0.001 per share as of September 30, 2025 and December 31, 2024.

Common Stock Issuances

Nine months Ended September 30, 2025

BioStem Technologies, Inc. and Subsidiaries
Condensed Notes to the Consolidated Financial Statements
For the Three and Nine Months Ended September 30, 2025 and 2024
(Unaudited)

The Company issued 94,052 of fully vested restricted stock to executives, directors and key employees for services rendered. See also Note 10 for further disclosures on restricted stock units granted as compensation for services.

The Company issued 1,140 shares of common stock for \$15,000 of services, based on the market price of the Company's stock on the date of grant.

The Company issued 16,667 shares of common stock for the exercise of warrants and received cash proceeds of \$33,334.

The Company issued 10,000 shares of common stock at a purchase price of a \$1.50 to a former employee and received cash proceeds of \$15,000.

Nine months Ended September 30, 2024

The Company issued 3,462 shares of common stock for \$184,091 of services, based on the market price of the Company's stock on the date of grant.

The Company issued 175,001 shares of common stock for the exercise of warrants and received cash proceeds of \$350,007.

The Company issued 2,942 shares of common stock for the conversion of \$15,210 of outstanding debt and accrued interest.

During the nine months ended September 30, 2024, the Company agreed to repurchase and retired 117,359 shares of common stock for \$1.00 that had been previously issued to a service provider.

Note 10 – Stock Based Compensation

Common Stock Warrants and Warrants for Services

On April 8, 2024, the Company entered into an agreement with a service provider to provide certain services until December 27, 2025 (the "Service Agreement") in exchange for 60,000 shares of restricted common stock with a fair value of \$860,400 based on the market price of the Company's common stock on the grant date. Further, the Company issued the service provider a common stock purchase warrant ("Warrant") which permits the service provider to purchase 50,000, 50,000, and 100,000 shares of the Company's common stock at a price of \$4.00 per share, \$5.00 per share, and \$6.00 per share, respectively. The Warrant was immediately exercisable at any time, in whole or in part, by the service provider from April 8, 2024, to April 8, 2029. The total estimated grant date fair value of the Warrant using the Black-Scholes option pricing model was \$1,943,500 to be recognized into expense over the term of the service provider's agreement. The following inputs were utilized in the Black-Scholes option pricing model to estimate the Warrant fair value: common stock price \$10.78, exercise price of \$4 - \$6, volatility of 124.34%, and risk-free rate of 4.43%.

The initial value of the common stock and warrants was reflected as an increase to additional paid in capital and prepaid expenses in the aggregate amount of \$2,803,900 upon issuance. The fair value of these stock-based payments was being amortized into expense over the service term of the agreement through December 2025. During the nine months ended September 30, 2025, the Service Agreement was terminated, and the Company recognized the remaining prepaid expense balance of \$1,611,796 as stock-based compensation expense which is included in general and administrative services on the accompanying condensed consolidated statements of operations.

During the nine months ended 2024, the Company amortized \$389,849 of these stock-based payments into expense which was classified within general and administrative expense on the consolidated statements of operations.

BioStem Technologies, Inc. and Subsidiaries
Condensed Notes to the Consolidated Financial Statements
For the Three and Nine Months Ended September 30, 2025 and 2024
(Unaudited)

As of September 30, 2025, the remaining unrecognized prepaid amount related to the common stock and warrants issued for services was \$0.

The following table presents the Company's common stock warrant activity during the three and nine months ended September 30, 2025:

	Number of Shares Underlying Warrants	Weighted Average Exercise Price	Weighted Average Remaining Term (Years)
Outstanding as of December 31, 2024	2,060,134	\$ 2.26	3.71
Exercised	(16,667)	2.00	-
Outstanding and exercisable as of March 31, 2025	2,043,467	\$ 2.00	3.46
Outstanding and exercisable as of June 30, 2025	2,043,467	\$ 2.27	3.21
Outstanding and exercisable as of September 30, 2025	2,043,467	\$ 2.27	2.99

Stock Options

The fair value of service-based stock options granted to employees and non-employees is estimated on the grant date using the Black-Scholes valuation model with the following assumptions for the nine months ended September 30, 2025 and 2024:

	September 30, 2025	September 30, 2024
Dividend yield	0%	0%
Expected term	6 years	6 years
Risk-free interest rates	3.93% - 4.42%	3.50% - 4.84%
Expected volatility	104.47% - 106.98%	110.00% - 123.95%

Dividend Yield – The dividend yield is assumed to be zero as the Company has never paid dividends and has no current plans to do so.

Expected Term – The expected term represents the period that the Company's stock-based awards are expected to be outstanding. The Company determines the expected term using the simplified method as the Company does not have sufficient historical information to develop reasonable expectations about future exercise patterns and post-vesting employment termination behavior. The simplified method deems the term to be the average of the time-to-vesting and the contractual life of the options.

Expected Volatility – Since the Company does not have a sufficient trading history of its common stock, the expected volatility is derived from the average historical stock volatilities of several unrelated public companies within the Company's industry that the Company considers to be comparable to its business over a period equivalent to the expected term of the stock option grants.

Fair Value of Common Stock – The fair value of common stock is based on the closing price of the Company's common stock, as reported on the OTC on the date of grant.

The following table summarizes activity under the Company's stock option plans for service-based and market-based stock options during the three and nine months ended September 30, 2025:

BioStem Technologies, Inc. and Subsidiaries
Condensed Notes to the Consolidated Financial Statements
For the Three and Nine Months Ended September 30, 2025 and 2024
(Unaudited)

	Number of Shares Underlying Options	Weighted Average Exercise Price	Weighted Average Remaining Term (Years)	Intrinsic Value
Outstanding as of December 31, 2024	6,074,062	\$ 2.45	7.61	\$ 69,204,153
Granted	370,311	10.64	-	-
Forfeited	(92,776)	5.64	-	-
Outstanding as of March 31, 2025	6,351,597	2.88	7.48	\$ 69,670,788
Granted	2,855	14.96	-	-
Forfeited	(83,322)	5.84	-	-
Outstanding as of June 30, 2025	6,271,130	\$ 2.05	7.24	\$ 62,847,175
Granted	74,248	9.38	-	-
Forfeited	(135,576)	6.92	-	-
Outstanding as of September 30, 2025	6,209,802	\$ 2.17	6.96	\$ 15,035,690
Exercisable as of September 30, 2025	5,538,893	\$ 2.08	6.62	\$ 14,914,888

The weighted-average grant date fair value of options granted during the nine months ended September 30, 2025 was \$7.80. During the three and nine months ended September 30, 2025 and 2024, the Company recognized \$504,787 and \$528,000 and \$2,732,673 and \$4,458,557, respectively, of stock-based compensation in connection with service-based and market-based option grants (see below) which is included in general and administrative expenses on the condensed unaudited consolidated statements of operations. As of September 30, 2025, total unrecognized stock-based compensation expense for service-based option grants was \$4,145,504, which is expected to be recognized over a straight-line basis over a weighted-average period of 2.39 years.

Intrinsic value is measured based on the closing market price of Company's common stock on the OTC market as of September 30, 2025 and the options exercise price times the number of options outstanding or exercisable whose exercise price is below the market price.

Market-Based Stock Option Grants

In October 2022, the Board of Directors granted 2,250,000 options at an exercise price of \$2.00, to both the Company's Chief Executive Officer ("CEO") and Chief Operating officer ("COO") for a total of 4,500,000 options with vesting based on Sustained Market Capitalization targets which were fully met during the three months ended March 31, 2025. As of September 30, 2025, the Sustained Market Capitalization targets had been met and all 4,500,000 options were vested and exercisable. During the nine months ended September 30, 2025 and 2024, \$1,438,538 and \$3,713,642 of stock-based compensation expense was recognized related to these market-based option grants.

Restricted Stock Units ("RSUs")

During the nine months ended September 30, 2025, RSU grants were to key employees and the Company's CEO and COO. The RSUs granted vest as follows: 33% on the first anniversary of the grant date with quarterly vesting over two (2) years thereafter. The aggregate grant date fair value of RSUs granted during the nine months ended September 30, 2025 was \$4,861,100 which will be expensed over the vesting period.

The fair value of restricted stock is based on the closing price of the Company's common stock on the OTC market on the date of grant.

The following table summarizes the restricted stock unit activity during the three and nine months ended September 30, 2025:

BioStem Technologies, Inc. and Subsidiaries
Condensed Notes to the Consolidated Financial Statements
For the Three and Nine Months Ended September 30, 2025 and 2024
(Unaudited)

	Shares Outstanding	Weighted Average Grant Date Fair Value
Unvested balance - December 31, 2024	359,351	\$ 10.01
Granted	361,917	10.55
Vested	(32,252)	9.96
Unvested balance - March 31, 2025	689,016	10.28
Granted	2,855	14.01
Vested	(32,252)	9.96
Forfeited	(7,623)	14.89
Unvested balance - June 30, 2025	651,996	\$ 10.28
Granted	128,787	8.11
Vested	(28,018)	9.98
Forfeited	(44,731)	10.62
Unvested balance - September 30, 2025	708,034	\$ 9.92

During the nine months ended September 30, 2025 and 2024, we recognized stock-based compensation on the restricted stock units of \$1,665,083 and \$0, respectively. As of September 30, 2025, unrecognized stock-based compensation on unvested RSUs was \$6,202,880 which will be recognized through December 2028 over a weighted average period of 2.15 years.

Note 11 – Commitments and Contingencies

Operating leases

On March 15, 2024, the Company entered into a thirty-eight (38) month lease for office space commencing April 1, 2024. On April 1, 2024, the Company occupied its new expanded office space in Fort Lauderdale, Florida and received the months of April and May rent free. Monthly lease payments are \$10,159, \$10,329 and \$10,504 for the periods June 1, 2024 through May 31, 2025, June 1, 2025 through May 31, 2026 and June 1, 2026 through May 31, 2027, respectively. Further, the Company executed a lease for office equipment which commenced April 2024 and requires monthly lease payments of \$1,029 through July 2027.

Upon the lease commencing, the Company recognized an operating right-of-use asset and operating lease liabilities of approximately \$340,000 for the present value of the lease payments required over the term of the lease using an incremental borrowing rate of 12.00%

On May 15, 2025, an additional lease for office space commenced located in Fort Lauderdale, Florida. The lease is for a period of twenty-four months through May 2027 and requires monthly lease payments of \$9,713 through May 2026 and then \$9,872 for the remaining lease term.

Upon the lease commencing, the Company recognized an operating right-of-use asset and operating lease liabilities of approximately \$214,000 for the present value of the lease payments required over the term of the lease using an incremental borrowing rate of 11.31%

Future payments required on the operating lease liabilities through May 2027 are as follows:

BioStem Technologies, Inc. and Subsidiaries
Condensed Notes to the Consolidated Financial Statements
For the Three and Nine Months Ended September 30, 2025 and 2024
(Unaudited)

Year Ending December 31,		
2025 (remaining)	\$	77,483
2026		259,718
2027		111,458
Total		448,659
Less present value discount		(61,503)
Total operating lease liabilities	\$	387,156

Legal Matters

From time to time, claims are made against the Company in the ordinary course of business, which could result in litigation. Claims and associated litigation are subject to inherent uncertainties and unfavorable outcomes could occur, such as monetary damages, fines, penalties, or injunctions prohibiting the Company from selling one or more products or engaging in other activities. The occurrence of an unfavorable outcome in any specific period could have a material adverse effect on the Company's results of operations for that period or future periods. The Company is not presently a party to any pending or threatened legal proceedings.

Note 12 – Federal and State Income Taxes

The Company recorded an income tax expense of approximately \$0.7 million and \$2.3 million and \$2.2 million and \$5.8 million from continuing operations for the three and nine months ended September 30, 2025 and 2024, respectively.

As of September 30, 2025, the Company utilized all of their available federal and state net operating loss carryforwards ("NOLs") for federal income tax purposes and all of their state NOLs totaling \$27.7 million and \$23.1 million, respectively. The Company's effective tax rate ("ETR") for the nine months ended September 30, 2025 and 2024 was 32.44% and 26.3%, respectively. The Company's ETR increased from the first quarter of 2024 due to the benefit of decreased apportionment to the State of Florida, partially offset by the change in permanent adjustments.

Note 13 – Segment Reporting

Operating segments are defined as components of an entity for which separate financial information is available and that is regularly provided to the CODM in deciding how to allocate resources to an individual segment and in assessing performance. The Company's Chief Executive Officer comprises the Company's CODM. The CODM reviews financial information presented on a consolidated basis for purposes of making operating decisions, allocating resources, and evaluating financial performance. The CODM uses consolidated revenue, gross profit, net income(loss) and to assess performance, evaluate cost optimization, and allocate resources, including personnel-related and financial or capital resources, in the annual budget and forecasting process, as well as budget-to-actual variances on a monthly basis. As such, the Company has determined that it operates as one operating and reportable segment. Segment assets, liabilities and shareholders' equity (deficit) is presented the same as disclosed on the consolidated balance sheets.

The following tables set forth significant expense categories and other specified amounts included in consolidated net income that are otherwise regularly provided to the CODM for the three and nine months ended September 30, 2025 and 2024:

BioStem Technologies, Inc. and Subsidiaries
Condensed Notes to the Consolidated Financial Statements
For the Three and Nine Months Ended September 30, 2025 and 2024
(Unaudited)

	Three Months Ended September 30,		Nine Months Ended September 30,	
	2025	2024	2025	2024
Revenue	\$ 10,473,402	\$ 18,412,816	\$ 37,403,597	\$ 47,016,700
Cost of goods sold	1,204,794	4,238,658	2,743,409	10,211,258
Segment profit	9,268,608	14,174,158	34,660,188	36,805,442
General and administrative	1,683,373	975,390	7,968,836	5,704,446
Research and development	30,556	6,513	81,456	9,633
Sales and marketing	263,688	154,138	503,147	413,726
Professional fees	3,936,031	2,583,037	13,130,629	4,924,192
Compensation and related	1,848,526	1,109,204	5,992,901	2,875,612
Depreciation and amortization	57,644	54,038	172,344	158,770
Interest expense (income), net	(143,284)	139,288	(239,686)	521,471
Other expense	123,345	-	123,345	2,497
Income tax expense	707,677	2,332,648	2,247,428	5,831,273
Segment expense	8,507,556	7,354,256	29,980,401	20,441,620
Segment net income	\$ 761,052	\$ 6,819,902	\$ 4,679,787	\$ 16,363,822

Note 14 – Restatement

The Company has previously filed with the Securities and Exchange Commission (“SEC”) a registration statement on Form 10 along with Amendments 1 and 2 to the Form 10 on September 27, 2024, November 27, 2024 and January 23, 2025, respectively (collectively referred to as the “Forms 10s”). These Form 10s include the Company’s consolidated financials for the years ended December 31, 2023 and 2022 and interim condensed consolidated financial statements for the six- and nine-month periods ended June 30, 2024 and September 30, 2024. On October 28, 2025, the Company filed with the SEC an application for withdrawal of its previously filed Form 10’s and requested withdrawal of the Company’s Registration Statement on Form 10, initially filed with the SEC on September 27, 2024, together with all exhibits and amendments thereto (the “Registration Statement”).

On September 11, 2025, the Company filed with the Over-the-Counter Market (“OTC”) a notice of non-reliance on previously issued financial statements, specifically, the Company’s audited financial statements for the year ended December 31, 2023 (“2023 Annual Financial Statements”), the unaudited condensed consolidated financial statements for the quarters ended March 31, 2024, June 30, 2024 and September 30, 2024 (the “2024 Interim Financial Statements”), the unaudited consolidated financial statements for the year ended December 31, 2024 (the “2024 Annual Financial Statements”), and the unaudited consolidated financial statements for the interim periods ended March 31, 2025 and June 30, 2025 (the “2025 Interim Financial Statements”), all of which were filed on the OTC Disclosure & News Service (the “DNS”), which should no longer be relied upon. The 2023 and 2024 Annual Financial Statements, the 2024 Interim Financial Statements and the 2025 Interim Financial Statements, are collectively referred to as the “Filed Financial Statements”.

The Filed Financial Statements recognized revenue and the consideration payable to our Distributor, who is our customer, in the form of a BFSF (see Note 4) on the gross basis. The amount invoiced by the Company to the Distributor for purchased products was previously reported as revenue on a gross basis and the BFSF charged back to us by the customer was recognized within sales and marketing expense on a gross basis.

In accordance with ASC 606-10-32-25, consideration payable to a customer includes cash amounts that an entity pays. An entity shall account for consideration payable to a customer as a reduction of the transaction price and, therefore, within revenue unless the payment to the customer is in exchange for a distinct good or service that the customer transfers to the entity.

We previously applied this guidance incorrectly in the Filed Financial Statements and treated the BFSF as a payment to the Distributor for a distinct service. However, given we recognize revenue upon shipment of our products to our Distributor the services performed by the Distributor as Bona Fide Services would not directly benefit the Company and should not be considered distinct services.

BioStem Technologies, Inc. and Subsidiaries
Condensed Notes to the Consolidated Financial Statements
For the Three and Nine Months Ended September 30, 2025 and 2024
(Unaudited)

We have amended and restated our revenue recognition policy which has been disclosed in Note 4. As required by ASC 606-10-32-25, the BFSF payable to the Distributor will be reflected as a reduction in transaction price. Therefore, the Filed Financial Statements overstated our consolidated revenues and sales and marketing expenses as well as overstated our current liabilities as we incorrectly presented BFSF expense and BFSF payable on a gross basis rather than presenting net within our consolidated revenues and net within consolidated accounts receivable.

The tables below summarize and reflect the financial statement line items impacted by this error correction for all periods previously issued in the Filed Financial Statements. Given the correction of the error is a presentation matter, the error correction had no impact on our consolidated net income (loss) or earnings (loss) per share in the restated financial statement.

BioStem Technologies, Inc. and Subsidiaries
Condensed Notes to the Consolidated Financial Statements
For the Three and Nine Months Ended September 30, 2025 and 2024
(Unaudited)

Impact of the Restatement as of and for the Year Ended December 31, 2023

Statement of Operations Data (Unaudited)	Year Ended December 31, 2023		
	As Previously Reported	Adjustment	As Restated
Revenue, net	\$ 16,685,405	(9,536,800)	7,148,605
Gross profit	\$ 15,424,847	(9,536,800)	5,888,047
Sales and marketing expenses	\$ 11,986,385	(9,536,800)	2,449,585
Total operating expenses	\$ 23,203,816	(9,536,800)	13,667,016
Net income (loss)	\$ (8,482,984)	-	(8,482,984)

Balance Sheet Data (Unaudited)	As of December 31, 2023		
	As Previously Reported	Adjustment	As Restated
ASSETS			
Accounts receivables, net	\$ 11,371,730	(7,787,211)	3,584,519
Total current assets	\$ 12,599,053	(7,787,211)	4,811,842
Total assets	\$ 14,560,291	(7,787,211)	6,773,080
LIABILITIES			
Bonafide services fees payable	\$ 7,787,211	(7,787,211)	-
Total current liabilities	\$ 15,620,888	(7,787,211)	7,833,677
Total liabilities	\$ 15,904,667	(7,787,211)	8,117,456
Total liabilities & equity	\$ 14,560,291	(7,787,211)	6,773,080

BioStem Technologies, Inc. and Subsidiaries
Condensed Notes to the Consolidated Financial Statements
For the Three and Nine Months Ended September 30, 2025 and 2024
(Unaudited)

Impact of the Restatement as of and for the Year Ended December 31, 2024

Statement of Operations Data (Unaudited)	Year Ended December 31, 2024		
	As Previously Reported	Adjustment	As Restated
Revenue, net	\$ 301,827,302	(232,168,882)	69,658,420
Gross profit	\$ 288,081,477	(232,166,341)	55,915,136
Sales and marketing expenses	\$ 236,058,090	(232,189,386)	3,868,704
Total operating expenses	\$ 256,880,836	(232,168,883)	24,711,953
Net income	\$ 31,884,321	-	31,884,321

Balance Sheet Data (Unaudited)	As of December 31, 2024		
	As Previously Reported	Adjustment	As Restated
ASSETS			
Accounts receivables, net	\$ 104,980,085	(81,873,058)	23,107,027
Total current assets	\$ 133,761,109	(81,906,557)	51,854,552
Total assets	\$ 140,375,727	(81,873,058)	58,502,669
LIABILITIES			
Bonafide services fees payable	\$ 81,873,058	(81,873,058)	-
Total current liabilities	\$ 99,169,960	(81,872,288)	17,297,672
Total liabilities	\$ 99,500,195	(81,872,288)	17,627,907
Total liabilities & equity	\$ 140,375,727	(81,873,058)	58,502,669

BioStem Technologies, Inc. and Subsidiaries
Condensed Notes to the Consolidated Financial Statements
For the Three and Nine Months Ended September 30, 2025 and 2024
(Unaudited)

Impact of the Restatement as of and for the Quarters ended June 30, 2025, and March 31, 2025

Statement of Operations Data (Unaudited)	Three Months Ended June 30, 2025			Three Months Ended March 31, 2025		
	As Previously Reported	Adjustment	As Restated	As Previously Reported	Adjustment	As Restated
Revenue, net	\$ 49,296,495	(38,333,321)	10,963,174	72,528,112	(56,561,091)	15,967,021
Gross profit	\$ 48,611,318	(38,333,321)	10,277,997	71,674,674	(56,561,091)	15,113,583
Sales and marketing expenses	\$ 39,608,471	(38,333,321)	1,275,150	57,684,468	(56,561,091)	1,123,377
Total operating expenses	\$ 48,498,558	(38,333,321)	10,165,237	66,425,349	(56,561,091)	9,864,258
Net income (loss)	\$ (564,360)	(2)	(564,362)	4,483,096	1	4,483,097

Balance Sheet Data (Unaudited)	As of June 30, 2025			As of March 31, 2025		
	As Previously Reported	Adjustment	As Restated	As Previously Reported	Adjustment	As Restated
ASSETS						
Accounts receivables, net	\$ 67,663,476	(52,621,865)	15,041,611	109,657,309	(85,525,228)	24,132,081
Total current assets	\$ 104,925,782	(53,052,068)	51,873,714	142,032,858	(85,558,728)	56,474,130
Total assets	\$ 112,610,960	(52,621,865)	59,989,095	149,313,514	(85,525,228)	63,788,286
LIABILITIES						
Bonafide services fees payable	\$ 52,621,865	(52,621,865)	-	85,525,228	(85,525,228)	-
Total current liabilities	\$ 64,156,179	(52,620,990)	11,535,189	101,492,369	(85,524,459)	15,967,910
Total liabilities	\$ 64,522,487	(52,620,991)	11,901,496	101,793,649	(85,524,458)	16,269,191
Total liabilities & equity	\$ 112,610,960	(52,621,865)	59,989,095	149,313,514	(85,525,228)	63,788,286

Impact of the Restatement as of and for Quarters ended September 30, 2024, June 30, 2024, and March 31, 2024

Statement of Operations Data (Unaudited)	Three Months Ended September 30, 2024			Three Months Ended June 30, 2024		
	As Previously Reported	Adjustment	As Restated	As Previously Reported	Adjustment	As Restated
Revenue, net	\$ 82,556,740	(64,143,924)	18,412,816	74,491,996	(57,952,327)	16,539,669
Gross profit	\$ 78,318,082	(64,143,924)	14,174,158	70,744,100	(57,952,328)	12,791,772
Sales and marketing expenses	\$ 65,187,066	(64,159,302)	1,027,764	58,997,880	(57,952,327)	1,045,553
Total operating expenses	\$ 69,025,742	(64,143,422)	4,882,320	61,924,969	(57,952,327)	3,972,642
Net income	\$ 6,820,403	(502)	6,819,901	6,286,028	(1)	6,286,027

Balance Sheet Data (Unaudited)	As of September 30, 2024			As of June 30, 2024		
	As Previously Reported	Adjustment	As Restated	As Previously Reported	Adjustment	As Restated
ASSETS						
Accounts receivables, net	\$ 81,072,073	(62,993,743)	18,078,331	78,190,570	(60,792,973)	17,397,597
Total current assets	\$ 101,383,452	(62,993,743)	38,389,710	87,982,987	(60,792,973)	27,190,014
Total assets	\$ 104,200,464	(62,993,743)	41,206,721	91,185,995	(60,792,973)	30,393,022
LIABILITIES						
Bonafide services fees payable	\$ 62,993,743	(62,993,743)	-	60,792,973	(60,792,973)	-
Total current liabilities	\$ 81,010,915	(62,984,828)	18,026,087	75,470,314	(60,787,982)	14,682,332
Total liabilities	\$ 81,369,253	(62,993,341)	18,375,912	75,848,349	(60,787,983)	15,060,366
Total liabilities & equity	\$ 104,200,464	(62,993,743)	41,206,721	91,185,995	(60,792,973)	30,393,022

BioStem Technologies, Inc. and Subsidiaries
Condensed Notes to the Consolidated Financial Statements
For the Three and Nine Months Ended September 30, 2025 and 2024
(Unaudited)

Impact of the Restatement as of and for Quarters ended September 30, 2024, June 30, 2024, and March 31, 2024
(Continued)

Statement of Operations Data (Unaudited)	Three Months Ended March 31, 2024		
	As Previously Reported	Adjustment	As Restated
Revenue, net	\$ 41,904,213	(29,839,998)	12,064,215
Gross profit	\$ 39,679,509	(29,839,998)	9,839,511
Sales and marketing expenses	\$ 30,547,721	(29,836,166)	711,555
Total operating expenses	\$ 35,071,396	(29,839,979)	5,231,417
Net income	\$ 4,442,075	(1,184,182)	3,257,893

Balance Sheet Data (Unaudited)	As of March 31, 2024		
	As Previously Reported	Adjustment	As Restated
ASSETS			
Accounts receivables, net	\$ 41,622,643	(29,939,349)	11,683,294
Total current assets	\$ 43,734,136	(30,019,948)	13,714,188
Total assets	\$ 45,674,089	(29,939,285)	15,734,804
LIABILITIES			
Bonafide services fees payable	\$ 29,839,849	(29,839,849)	-
Total current liabilities	\$ 38,806,994	(28,783,656)	10,023,338
Total liabilities	\$ 39,032,078	(28,758,420)	10,273,658
Total liabilities & equity	\$ 45,674,089	(29,939,285)	15,734,804

BioStem Technologies, Inc. and Subsidiaries
Condensed Notes to the Consolidated Financial Statements
For the Three and Nine Months Ended September 30, 2025 and 2024
(Unaudited)

Note 15 - Subsequent Events

The Company has evaluated all transactions and events after the balance sheet date through November 13, 2025, the date on which these financials were available to be issued and has determined that no additional disclosures are required.